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Abstract
SYNTHETIC, SULFATED, LIGNIN-BASED ANTICOAGULANTS
by Akul Yugesh Mehta, Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2014.
Supervisor: Umesh R Desai
Chemoenzymatically synthesized low molecular weight lignin polymers have been previously
found to be potent inhibitors of a number of serine proteases via allosteric mechanisms targeting
heparin binding sites. Herein, we describe the creation of synthetic sulfated β-O4 lignin (SbO4L)
polymer, which is more homogenous compared to previous lignins with respect to its intermonomeric linkage. SbO4L is a selective inhibitor of thrombin and plasmin. SbO4L was found
to act via a unique mechanism targeting thrombin exosite 2 in a manner similar to platelet
glycoprotein Ibα (GPIbα). Advanced hemostasis and thrombosis assays demonstrated that
SbO4L acts via a dual mechanism: as an anticoagulant, by allosteric inhibition of thrombin
catalysis; and as an antiplatelet agent, by competing with platelet GPIbα. These mechanisms are
comparable in potency to low molecular weight heparins currently used in the market, indicating
that targeting exosite 2 may yield clinically useful drugs in the future. Since the β-O4 type lignin
was found to be selective for thrombin and plasmin, we hypothesized that other scaffolds from
lignins could be potent inhibitors of other serine proteases. In particular, we screened a library of
xviii

synthetic sulfated small molecules against factor XIa – an emerging target for prophylactic
anticoagulation. Our search identified a sulfated benzofuran trimer (a mimic of β-5 type linkage
found in lignins) as a potent inhibitor of factor XIa. Surprisingly, this inhibitor did not compete
with heparin. A plausible binding site in the A3 domain of factor XIa was proposed by using
molecular modeling techniques. The binding pose demonstrated good correlation with the
structure activity data from in vitro studies. Further confirmation that the apple domains were
required was proved by testing the trimer against recombinant catalytic domain. A 40-fold
decrease in activity was observed. A temperature-dependant perrin plot demonstrated that factor
XIa undergoes a large conformational change in the presence of the trimer, which is possibly
converting the enzyme back into the zymogen-like shape. In general, the synthetic sulfated
lignins can act as a useful foundation to develop anticoagulant, antiplatelet, and antiinflammatory molecules in the future.

xix

Chapter 1: Introduction
1.1 Blood, Coagulation and Hemostasis
Blood is an essential body fluid that helps transport nutrients to all cells of the body,
while simultaneously transporting metabolic waste products away from the cells for excretion.1
An average human being contains almost 4 liters of blood within the body. Part of this is made
up of proteins, which float in the liquid fraction of blood called plasma and are essential for
coagulation and transportation of nutrients. The other part of blood is composed of cells. Three
major types of cells make up the cellular composition of blood, namely: (a) Red blood cells
(erythrocytes) – essential for carrying oxygen to various tissues of the body. (b) White blood
cells (leucocytes) – essential for fighting infections and performing various protective functions.
(c) Platelets (thrombocytes) – essential for prevention of blood loss.1
In toto, these components of blood help perform a variety of functions such as supplying
nutrients and oxygen to various parts of the body; transporting waste products from various
tissues to the kidneys; lungs and liver for metabolism and excretion; protecting the body from
various infections; maintaining body pH, hydration and temperature; and coagulation in case of
injury. Thus, proper blood flow within the body is essential to maintain the homeostatic balance
of the body.1
To maintain appropriate blood flow conditions, procoagulant and anticoagulant factors
are present within the blood.2 In case of injury, excessive blood loss is prevented by the
1

procoagulant factors, which result in hemostasis. Simultaneously, anticoagulant factors help
maintain proper blood flow within the rest of the body. This balance of procoagulant and
anticoagulant factors is maintained by certain proteins and regulatory factors present in the blood
by a process known as the coagulation cascade, along with the platelet cells of the blood.2
1.2 The Coagulation Cascade
The coagulation cascade is composed of several proteins which are freely floating within
the blood in their inactive state or zymogen form (Figure 1). Upon injury or under pathological
conditions, these zymogens are activated in a sequential step by step manner via either the
intrinsic pathway (contact activation pathway) or the extrinsic pathway (tissue factor pathway).

Intrinsic
Pathway

The Coagulation Cascade

Injury to Blood Vessel
HMWK, PK
fXI

fXIa
fIX

fVIII

fIXa

fVIIIa
fV

Activated
Protein C

fVa
Prothrombin
(fII)

Injured Cells Release
Tissue Factor (TF)
fVII
fX fVIIa
Serpins +
PAR
TF
GAGs
fXa

fXIII

Thrombin
(fIIa)

Thrombomodulin
Fibrinogen
Protein C

fXIIIa

Fibrin

Plasminogen

Activated
PAR

Activates Platelets

fXIIa

GPIbα

fXII

Extrinsic
Pathway

Cross-linked
Fibrin Clot

Plasmin

Fibrin Clot
Degradation

tPA
Figure 1. The coagulation cascade of blood. In black are the procoagulant factors, while in grey

are the anticoagulant pathways. Thrombin (factor IIa) plays a key role in the cascade. It

2

catalyzes the conversion of soluble fibrinogen to insoluble fibrin which eventually leads to clot
formation by thrombin activated fXIIIa. It acts as a link between the cascade and platelets for
aggregation via binding to glycoprotein Ibα (GPIbα). It provides positive feedback to the cacade
by activating fXI, fVIII and fV, while also providing negative feedback in presence of
thrombomodulin via protein C pathway. Thrombin activity can be regulated by serpin-GAG
complexes. Image adapted from reference 3.3

In case of injury, there is damage to the endothelium which exposes the subendothelial
tissues (mainly composed of smooth muscle cells). These subendothelial cells express tissue
factor (TF) on their surface, which acts as a receptor for factor VII in turn activating it to form
factor VIIa.4,5 The TF-VIIa complex forms the extrinsic tenase complex which is capable of
activating factor X of the common pathway.6 On the other hand, the intrinsic pathway of
coagulation is a means of amplification of clot formation. It is activated when collagen (or other
anionic substances such as dextran sulfate) is exposed and forms a complex with high-molecular
weight kininogen (HMWK), prekallikrein and factor XII.7 Upon formation of this complex,
prekallikrein is activated to kallikrein and factor XII gets activated to form factor XIIa. Factor
XIIa in turn catalyzes the activation of factor XI to factor XIa, which subsequently activates
factor IX to factor IXa. Factor IXa is then capable of activating factor X of the common
pathway.8
The sequential activation via either of the pathways leads to the activation of factor X to
factor Xa from where the final common pathway initiates. Factor Xa catalyzes the conversion of
prothrombin (factor II) to thrombin (factor IIa). Thrombin has a large array of functions within
the cascade (Figure 1): (a) its primary role is to catalyze the conversion of soluble fibrinogen to
3

insoluble fibrin which ultimately leads to a “clot” that can plug the site of bleeding or damage;9
(b) it also activates factor XIII to factor XIIIa, which helps in cross-linking of the fibrin and
hence strengthens the clot;9 (c) it provides positive feedback to the coagulation cascade by
activating factors VIII,10 and factor V,11 which can dramatically propagate the clot formation by
forming the tenase and prothrombinase complexes with factor IXa and factor Xa, respectively;
(d) it can itself activate factor XI to factor XIa further providing positive feedback to the
cascade;12 (e) it can even activate platelets by binding to platelet glycoprotein Ibα (GPIbα) which
can help in platelet plug formation via activation and aggregation;13 (f) and lastly, thrombin also
plays a subtle anticoagulant role in the presence of thrombomodulin by activation of protein C,
which is capable of degrading factor VIIIa and factor Va, and has anti-inflammatory actions.14,15
The fibrin clot thus formed, along with the aggregated platelets forms a thrombus, which
helps in checking the blood loss and begin the wound healing process. Anticoagulant factors
such as heparin along with the serine protease inhibitors (serpins), antithrombin and heparin cofactor II, help maintain proper blood flow within the circulatory system away from the site of
thrombus formation.16 Furthermore, fibrinolytic pathways involving plasmin can help break
down already present clots within the body to restore normal blood flow once healing has
completed.17

1.3 The Platelets
Hematopoietic stem cells present within the bone marrow form the highly specialized
megakaryocyte cells, which function to produce and release platelets into the circulation. 18
Platelets are anuclear, discoid shaped cells, which range from 1-3 μm in diameter and 0.5 μm in
4

thickness and are the smallest cells found in the circulation.19,20 Blood vessel walls are lined with
a layer of endothelial cells, which play important physiological roles and participate directly in
hemostasis by interaction with blood components (Figure 2). They are also believed to be the
building blocks of vessels.21 The endothelial cells release nitric oxide and prostacyclin, which
help keep the platelets in their inactive state.
Underlying the layer of endothelial cells is a basement membrane. Below the membrane
is a layer of collagen matrix and smooth muscle cells. The basement membrane
(subendothelium) underlying the endothelium produces collagen on the surface. Platelets bind to
the collagen via a cell adhesion protein called the von Willebrand factor (vWF), which is present
in the blood (Figure 2). Thus, under physiological conditions collagen is not exposed to the
blood stream where platelets are present. However, upon injury, collagen its exposed to the
blood stream and can activate the platelets with the help of vWF present in the blood.22
Upon activation, platelets release alpha granules and dense granules which in turn
activate other platelets generating a chain reaction (Figure 2). The components from these
granules, such as ADP and thromboxane-2 (TXA-2) help in adhesion and aggregation of
platelets, and are also procoagulant and repairing in nature.23 Asprin, which is an antiplatelet
drug, targets the biosynthesis of TXA-2 to provide antiplatelet effects. Activation of platelets
also exposes phophatidylserine on the platelet surface, which activates factor Xa to enhance
thrombin generation and propagate the coagulation cascade to form a fibrin mesh.24 The unique
character demonstrated by activated platelets is that they undergo a dramatic shape-change,
producing pseudopods from their surface and obtaining a more stellate shape. Platelet shape
change is a complex process, which is controlled by proteins that regulate actin architecture.25
Such a platelet is then able to clump with other platelets to form the platelet plug.
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Figure 2. The role of platelets during injury. From left to right: During normal blood flow,
endothelial cells keep the platelets at rest by releasing nitric oxide (NO) and prostacyclin (PGI2).
The endothelial cells also act as a barrier preventing von Willebrand factor from interacting
with collagen. During injury, the endothelial layer is disrupted exposing the collagen to the Von
Willebrand factor. Binding of VWF to collagen provides a surface for interaction of platelet
surface integrins and glycoprotein Ibα. This causes the platelets to roll on the vessel wall and be
captured via stable adhesion even under flow. Interaction of collagen with GPVI stimulates the
spreading of the platelet and activation, which in turn releases feedback agonists ADP and
thromboxane-2 (TXA-2) causing recruitment of more platelets for activation. Furthermore,
activation of platelets exposes phosphatidylserine on platelet surface which provides a
procoagulant surface for thrombin activation. Together, aggregation of activated platelets and
thrombin mediated fibrin mesh formation lead to formation of platelet plug.
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Platelets mediate a number of vascular and cellular responses via a number of receptors.26,27
Since both coagulant factors and platelets assist in hemostasis, there is significant cross-talk
between the two systems via platelet receptors. The platelet receptors mainly involved in such
inter-play include:
1. Glycoprotein Ibα (GPIbα) - which is known to interact with thrombin, vWF and other
coagulation factors such as factor XI, XII, VIIa and kininogen.
2. Protease activated receptors PAR1, PAR3 and PAR4 – which are known receptors for
thrombin and are activated by thrombin.
3. Integrins like αIIbβ3 – which are known to bind with fibrinogen and vWF for adhesion.
Of these reactions, the GPIbα-thrombin reaction is critical for platelet-coagulation inter-play.
GPIbα is one of the most abundant surface receptors on platelets and thrombin is a versatile
catalytic enzyme. In fact, thrombin bound to GPIbα shows an increased catalytic ability towards
PAR activation suggesting that physiologically this complex might play a crucial role in
recruiting platelets during hemostasis induced by the coagulation system.

1.4 Structure of Thrombin
Thrombin is a ~36,000 Da globular enzyme which is formed from its precursor
prothrombin via cleavage of two peptide bonds, i.e., R320-I321 and R272-T273 (prothrombin
numbering).28-32 Upon activation thrombin is composed of an amino terminal light chain (“A”
chain ~6,000 Da) and a carboxy terminal heavy chain (“B” chain ~31,000 Da).30 The two chains
are covalently linked via single disulfide bond.32 Structurally, thrombin contains an active site
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with a catalytic triad, a sodium binding site and two allosteric electropositive sites called exosite
1 and exosite 2 (Figure 3).

Exosite 1

Active Site
Ser195 of
Catalytic
Triad

Sodium
Binding
Site

Exosite 2
Figure 3. The structure of human thrombin, showing the presence of a Ser195 at the active site
catalytic triad, a sodium binding site located close by, and two electropositive allosteric sites
called exosite 1 and exosite 2.
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Catalytic Triad and Mechanism
Thrombin is a serine protease. A specific serine residue (Ser195) within the active site is
essential for its protein cleaving catalytic activity (Figure 4A).33 This serine residue is a part of a
catalytic triad composed of Ser195, His57 and Asp102 (chymotrypsin numbering), which is
involved in a “ping-pong” catalysis involving the substrate and water (Figure 4B).34 The
hydroxyl group on the serine (seroxide) acts as a nucleophile and attacks the carbonyl carbon of
the peptide substrate to form a tetrahedral intermediate. To enhance this nucleophilicity of the
Ser195, the His57 lone pair on N3 or Nε of the imidazole ring is capable of accepting the
hydrogen of the hydroxyl of the Ser195. The Asp102 carboxylate hydrogen bonds with the other
imino group (N1 or Nδ) on the histidine imidazole to further catalyze the formation of the
tetrahedral intermediate. The nitrogen-carbon bond within the substrate finally breaks as the
peptide nitrogen accepts the hydrogen from the histidine to release the amine fragment of the
substrate (C-terminus). The carbonyl part of the substrate in turn forms a covalently linked acylenzyme intermediate. At this moment, water comes into the reaction to re-protonate the His57,
while the hydroxyl moiety attacks the carbonyl carbon of the acyl-enzyme intermediate to form
another tetrahedral intermediate. In the final step, the protonated His57 is capable of regenerating
the Ser195 hydroxyl while the tetrahedral intermediate structure breaks down to release the
carboxylate part of the substrate (N-terminus).
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B

Figure 4. Serine Protease Catalysis (A) Catalytic triad as observed in thrombin consisting of
Ser195, His57 and Asp102. (B) Mechanism of catalytic-triad mediated peptide bond cleavage in
serine proteases.
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Active Site Structure
Like other proteases, the active site of thrombin can be represented by the Schechter and
Berger nomenclature (Figure 5A).35 According to this nomenclature, the active site of a protease
is composed of subsites (S), wherein the sites on the enzyme which bind the substrate outwards
from the site of cleavage towards the amino-terminus of the substrate are numbered S1, S2,
S3,…Sn; while the sites on the enzyme which bind the substrate outwards from the site of
cleavage towards the carboxy-terminus of the substrate are numbered S1’, S2’, S3’,….Sn’.
Thrombin contains an acidic Asp189 residue at the bottom of the S1 pocket, which further
classifies it into the trypsin family of serine proteases (Figure 5C). However, unlike trypsin,
thrombin is highly selective in cleaving between Arg/Lys-Gly bonds. In fact, thrombin is
selectively able to cleave two specific Arg-Gly bonds out of 181 Arg/Lys-Xaa possible bonds on
fibrinogen to produce fibrin.36 The thrombin S1 pocket can possibly accommodate more bulkier
P1 groups than trypsin.37 Above the S1 pocket is a Trp215 residue, which forms a hydrophobic
base for the S2 and S4 binding pockets (Figure 5C). The active site of thrombin forms a
particularly deep cleft due to the insertion 60-loop above and the γ-loop (also called the autolysis
loop) below. The 60-loop helps form the S2 and S4 sites, while the γ-loop forms the S’ side
(Figure 5B). These loops help enhance thrombin specificity for substrates.38
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Figure 5. The active site of thrombin. (A) A structural depiction of the Schechter and Berger
nomenclature of serine protease active site pockets (depicted as S3, S2, S1, S1’, S2’ and S3’ on
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the enzyme) in relation to the protein substrate residues (depicted as P3, P2, P1, P1’, P2’ and
P3’). (B) A surface model of thrombin showing the different pockets of the active site with the
Ser195 of the catalytic triad in red. (C) The underlying chain structure and the defining amino
acid residues of the corresponding active site pockets.

The Sodium Binding Site
Located approximately 15 Å from the catalytic triad is a Na+ binding site formed by three
antiparallel β-strands of the B-chain (Met180-Tyr184a, Lys224-Tyr228, and Val213-Gly219)
and diagonally crossed by the Glu188-192 strand (Figure 6). The binding of sodium at this site is
highly selective over other monovalent cations like K+, Li+ or even Rb+. This Na+ is coordinated
to the main chain oxygens of Arg221a, Lys224 and four conserved water molecules. The binding
of Na+ forms a water mediated hydrogen bond with the Asp189 residue, which forms the base of
the S1 pocket and forms a charge-relay system with the catalytic triad. This binding therefore,
shifts thrombin from a “slow” to “fast” form. In fact, the binding of other ions like K+ in place of
Na+, shifts thrombin to an inactive or slow form.39
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Figure 6. Structural difference due to sodium binding relays into the catalytic triad. An overlay
of the fast sodium-bound form of thrombin (protein chain in blue, sodium as yellow ball, and
waters as red balls) and the slow sodium-free form of thrombin (protein chain in yellow, waters
as green balls) highlights the presence of a water mediated switch which links the sodium to the
catalytic triad of thrombin. Image is taken from reference 40.40
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Exosite 1
Located approximately around 20 Å away from the active-site catalytic triad, there is a
surface depression, which starts at the end of the P’ site of the enzyme. This surface depression is
mainly formed by insertion loops from 70-80 and is known as exosite 1 (Figure 7). Exosite 1 also
encompasses some bordering residues from the 37 loop and Lys109, Lys110 residues. Exosite 1
is electropositive in nature due to the presence of Lys36, Lys70, Lys81, Lys107, Lys109, and
Lys110; and Arg35, Arg67, Arg73, Arg75, Arg77A.32 The base of the exosite 1 is however
hydrophobic and is formed by the side chains of Tyr76 and Ile82. Exosite 1 is known to be
crucial for fibrinogen activation by thrombin.32,41 It is also known to interact with PARs,42 fV,43
fVIII,44 fXI,45 HCII,46 hirudin,47 and thrombomodulin.48

Exosite 2
Exosite 2 is a large, highly electropositive area located near the C-terminus of the heavy
chain of thrombin. As it binds heparin, this exosite is also known as the heparin binding exosite 2
and is roughly 200 Å2 in area (Figure 8). The electropositive residues within exosite 2 include:
Arg93, Arg97, Arg101, Arg126, Arg165, Lys169, Arg173, Arg175, Arg233, Lys235, Lys236
and Lys240.32,49 As most of these residues do not have a compensatory acidic residues, exosite 2
presents a highly electropositive surface, which can attract anionic molecules such as heparin. In
the zymogen form, the exosite 2 is covered by the F2 domain and is inaccessible in prothrombin,
pre-thrombin-1 and meizothrombin forms.50,51
Besides heparin, exosite 2 is known to interact with platelet receptor GPIbα,52
prothrombin fragments 1.2,50 chondroitin sulfate moiety of thrombomodulin,53 and fVIII.44 Some
15

exogenous ligands such as haemadin from Haemadipsa sylvestris leech is also known to interact
with thrombin exosite 2.54 Additionally, aptamers have been synthesized to interact with exosite
2 via their polyanionic nature.55,56

Figure 7. Structure of human thrombin showing all electropositive residues (arginines and
lysines) present on the exosite 1 (in yellow).
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Figure 8. Structure of human thrombin showing all electropositive residues (arginines and
lysines) present on the exosite 2 (in green).
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1.5 Thrombin Allostery
Allostery by definition is the phenomenon where a ligand binding at a site away from the
orthosteric/active site can affect the activity of the protein/enzyme. Thrombin is a highly plastic
enzyme.57 Its structural conformations and activity is highly regulated by the ligands it binds
within the blood. The three aforementioned sites, i.e., the sodium binding site, and the exosites 1
and 2, present extended surfaces away from the active site via which ligand binding can
demonstrate allosterism.
1.5.1. Sodium Binding Site and Thrombin Allostery
Binding of Na+ ions to thrombin has been shown to increase thrombin activity for well
over thirty years.58 However, since the lack of Na+ did not completely abolish activity, it was
concluded that Na+ is a positive allosteric effector of thrombin rather than a cofactor. Instead,
Na+ binding to thrombin has been shown to shift the enzyme from “slow” or low-activity form,
to a “fast” or high-activity form towards substrate hydrolysis.40 Moreover, it has also been shown
that the substrate specificity of these two forms of thrombin is widely different. The slow-form
of thrombin has been shown to be a stronger anticoagulant enzyme with greater activation of
protein C by binding to thrombomodulin and lack of activity against fibrinogen, PAR-1 and
other procoagulant factors. On the other hand, the fast Na+-bound form of thrombin demonstrates
higher procoagulant activity as a result of greater proteolytic activity towards fibrinogen, PAR-1
and other procoagulant factors.59,60 A structural link has been established between the Na+binding site and the catalytic triad which shows that a hydrogen bond network links the Na+ ion
to the Asp189 of the active site.61 Such an interaction could possibly account for the change in
activity and substrate specificity. If K+ is replaced in place of Na+ in the buffer, the enzyme shifts
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to a more inactive or slow form.39 This demonstrates the selectivity for, and the fine tuning by
Na+ at this site to maintain thrombin procoagulant activity and raises the possibility that this site
could be a switch to shift between allosteric forms.
1.5.2. Exosite 1 and Thrombin Allostery
Binding of different ligands to exosite 1 induces differential substrate specificity and
activity within the active site. For example, thrombomodulin binding at exosite 1 changes
thrombin substrate specificity from fibrinogen cleavage to protein C activation. 62,63 On the other
hand, hirugen binding mildly alters (either increases or decreases) catalytic efficiency of
thrombin towards an array of small chromogenic substrates and fibrinogen.64 A PAR receptor
fragment has been shown to resemble hirudin and alter thrombin specificity towards
chromogenic substrates.65 When bound to the exosite 1 of thrombin, PAR receptor fragments
also show a collapsed conformational change within the active site via a network of polar
interactions.66 A 15-nucleotide DNA aptamer (also called HD1 or TBA15) was found to bind to
thrombin exosite 1 causing inhibition of fibrinogen-clotting, platelet activation, and
thrombomodulin-dependent protein C activation.67-69 Several studies have also pointed towards
an allosteric link between exosite 1, the Na+ binding site and the active site, suggesting a strong
interplay among these sites.47,70,71
1.5.3. Exosite 2 and Thrombin Allostery
Thrombin exosite 2 is more electropositive compared to exosite 1, and hence it is known
to bind more anionic ligands like heparin. Although heparin binding does not induce allosteric
modification of enzyme structure or function, it plays a vital role in a bridging mechanism for
acceleration of inactivation by antithrombin III.49,72 Binding of anionic proteins/peptides has
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shown allosteric redirection or inhibition of the protease activity of thrombin. For example, the
binding of the activation peptide fragment 1.2 (F12) from prothrombin to exosite 2 of thrombin
results in the conversion of the enzyme to a zymogen like inactive state. The study also proposes
a link between exosite 2 and the sodium binding site.73 The fibrinogen γ’ chain is also known to
bind thrombin exosite 2 which results in inhibition of the proteolytic activity towards
proteinaceous substrates, possibly resulting from perturbation of the Na+ binding site, exosite 1
and the active site.74-76 Another DNA aptamer (DNA 60-18[29] or HD22), that is 29-nucleotides
in length was identified, which binds exosite 2 of thrombin and inhibits fibrin clot formation.77
On the flip-side, ecotin, an E. coli derived protein, decreases inhibition of thrombin by
heparin/antithrombin, and produces a two-fold increase in thrombin catalysis of fibrinogen
cleavage and inhibits thrombin-induced platelet aggregation via binding to exosite 2.78 Platelet
GPIbα was also found to bind at exosite 2 and inhibit thrombin’s fibrin formation ability as well
as activity towards other coagulation proteins, but it activates thrombin towards PAR activation,
thereby redirecting thrombin towards a pro-thrombotic role.79-82 More recently, a novel sulfated
pyranosic (13)-β-L-arabinan (Ab1), which is obtained from the green seaweed Codium
vermilara (Byropsidales) was found to inhibit thrombin via direct and indirect mechanisms by
binding to an allosteric site and inducing a conformational change.83 However, more evidence
needs to be presented to confirm that it does bind to exosite 2, since the authors have only
performed molecular dynamic simulations to propose the binding at this site.
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1.5.4. Link between Allosteric Sites
There exists some evidence that there is an allosteric network within thrombin, wherein
ligand binding at either exosite would affect other allosteric sites such as the other exosite, the
Na+ binding site or the active site. We have seen several examples above which demonstrate a
link between the exosites and the active site and the Na+ binding site. It is therefore feasible that
the two exosites could also be linked.
A study in 1997 was the first to demonstrate any kind of link between the two exosites.84
A more recent study involving several exosite ligands such as, HD1, HD22, γ’-peptide, heparin,
γA/γA-fibrin/fibrinogen, and prothrombin fragment 2 (FP12), has shown that there is long range,
allosteric, bidirectional communication between the exosites 1 and 2 of thrombin.85 A
contradictory study involving mutagenesis gave some evidence that exosite 2 is an independent
ligand binding site, but there is a link between the exosite 1 and the Na + binding site and the
active site.62 In comparison to the studies linking the two exosites using covalent fluorescent
labels and surface-bound proteins in SPR, this study involved highly unnatural thrombin mutants
with loops stabilized by engineered disulfide bonds within exosite 1 and the Na+ binding site.
Hence, interpretation of either of the results may be skewed due to experimental conditions, and
care should be taken in not concluding possibilities or impossibilities about a link existing
between the two exosites in a natural wild-type thrombin.
The occurrence of thrombin in such a vast variety of activity states due to various ligand
binding, has led to a newer “ensemble view of thrombin allostery”, wherein thrombin can exist
in various activation states in equilibrium and depending upon the ligands that bind to it a certain
state may predominate over others.86 Thus thrombin can be thought of as a “Swiss Army Knife”

21

within the coagulation cascade, which can be used and directed to a variety of utilities depending
on the body’s needs by various “hands” (or ligands). It also offers the development of newer
ligands to redirect this knife into the safest possible direction and use it more for benefit than
harm.

1.6 Sulfated Tyrosine Containing Proteins Involved in Hemostasis
Tyrosine sulfates were first detected in 1984.87 Yet even 30 years later, there is little
known about the action of this post translational modification. From an evolutionary point of
view, sulfation of tyrosines is a post translational modification, which is even found in plants. In
humans (and mammals), sulfated tyrosine containing proteins are present mainly in the
cardiovascular system, and especially in the blood.88 However, little is known about the function
of these groups within these proteins. Sulfated tyrosines are quickly gaining importance as a
novel post translational modification, and people are realizing sulfated-tyrosine binding sites
could possibly be targeted to obtain highly specific and allosteric drugs.
Tyrosine sulfation is carried out by tyrosylprotein sulfotransferase (TPST) enzyme. There
are two isoforms of this enzyme, TPST-1 and TPST-2. Both TPST-1 and TPST-2 are found
throughout the body at varying expression levels and use 3′-phosphoadenosine 5′-phosphosulfate
(PAPS) as a sulfate donor (Figure 9).89,90 It is of interest that the specificity of these enzymes to
catalyze tyrosine sulfation is also different. Hence the expression of these enzymes seems to
control important physiological outcomes. In fact, shear stress is known to play a role in the
expression levels of these enzymes within endothelial cells, thereby further implicating the role
of protein tyrosine sulfation in blood vessel pathologies.91
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Figure 9. Tyrosine sulfation reaction as catalyzed by tyrosylprotein sulfotransferase (TPST)
enzymes in the presence of 3′-phosphoadenosine 5′-phosphosulfate (PAPS).

Sulfated tyrosines are often located adjacent to negatively charged groups such as
aspartates and glutamates. These sulfated tyrosine rich anionic peptides (STRAPs) are present in
proteins that are essential for cell adhesion, immune response, and coagulation.88,90,92 These
STRAPs could provide selective interactions as there are no sequences in the literature, which
were absolutely identical. This implies that these interactions are highly specific for certain
characteristic features and mimicking them could provide a useful approach for drug design and
development.
There are additional proteins found apart from those in the blood, which also contain
sulfated tyrosines, such as gastrointestinal hormones (gastrin/CCK family), certain digestive
enzymes, growth and developmental hormones and neuroendocrine peptides.
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88,90,92

Yet no

STRAP is absolutely identical, further implying that mimicking STRAPs could provide useful
therapies in not just hemostatic disorders but also inflammatory, neuronal, gastrointestinal and
developmental disorders.

1.7 Structure and Functions of GPIbα
Glycoprotein Ibα (GPIbα) is a 626 amino acid (Uniprot ID: P07359) long surface
glycoprotein present on platelets. GPIbα exists as a complex along with GPIbβ, GPIX and GPV
to form the GPIb-IX-V complex (Figure 10).93,94 The long chain of GPIbα is split into 4 regions:
N-terminal ligand binding domain (1-282), sialomucin core domain which acts as a linker, a
transmembrane domain (506-526), and a cytoplasmic tail.
The N-terminal ligand binding domain is the business end of the protein that is
extracellular and interacts with several ligands. It consists of an N-terminus capping sequence (135), seven tandem leucine rich repeats (LRR) (36-200) which are 24 amino acids in length, a Cterminal flanking sequence (201-268), which forms a knot due to two disulfide linkages, and
finally ends in a sulfated tyrosine rich anionic peptide (STRAP) region (269-282) (Figure
10A).95,96 The structure of the N-terminal domain is almost “hook-like” and is involved in
adhesion as well as signaling functions. The following interactions mediate the majority of the
functions of the N-terminus of GPIbα (Figure 10B):
1. Adhesion: Interaction with von Willebrand Factor (vWF), thrombospondin (TSP), P-selectin
and integrin alpha M (ITGAM/αMβ2/MAC-1).
2. Procoagulant functions: Interaction with α-thrombin, kininogen, factor XI and XII.
3. Signalling: via GPVI, ITGAM/MAC-1 and FcγRIIa,
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Figure 10. The GPIb-IX-V complex. (A) Cartoon representation of the GPIb-IX-V complex,
showing the leucine-rich repeats, disulfide looped N- and C-terminal flanks, sulfated tyrosine
containing sequences, and phosphorylation sites of the cytoplasmic tails.(B) Shows the
functional binding sites of various ligands on the GPIb-IX-V complex. CaM : Calmodulin; FXI :
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factor XI; FXII : factor XII; TSP: Thrombospondin-1; VWF : von Willebrand factor. Image
taken from reference 96.96
The length of the sialomucin core of GPIbα appears to be an important factor in
regulating the availability of the N-terminus sequence for ligand binding, thus making it devoid
of steric hindrance from platelet surface molecules.97 Hence the sequence is crucial for adhesion
functions of platelets. The sialomucin chain is also recognized by cell wall proteins of bacteria
such as Streptococcus gordonii to provide bacteria-platelet interaction.98 However, other bacteria
require the N-terminal region of the protein, or bridging mechanism between GPIbα and vWF for
bacteria-platelet interactions.99-102 The sialomucin core is also important for binding fVIIa, which
might play a role in tissue factor-independent thrombin generation on activated platelet
surface.103
The intracellular cytoplasmic tail contains a filamin and signaling protein 14-3-3ζ binding
region which are possibly involved in intracellular signaling.104,105 The 14-3-3ζ has been
implicated in a toggle-switch mechanism which controls extracellular binding of vWF.106
Filamin binding is believed to play roles in GPIbα-dependent adhesion, platelet shape and size,
as well as raft localization of various receptors including the GPIb-IX-V complex.96 However,
the exact consequences of the interaction remain more or less a mystery.
Upon proteolytic digestion with Ca2+ activated protease calpain, the extracellular terminal
region sheds off to give the soluble form of GPIbα, known as glycocalicin, which is present at
normal levels of 1-3 μg/ml of blood.93,107,108 Apart from these functions, there is also evidence to
show that GPIb-IX complex could be a regulator of systemic inflammation via interaction with
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αMβ2 (MAC-1), and targeting this could prove promising as an anti-inflammatory and
antithrombotic for sepsis and endotoxemia.109-111

1.8 Interaction between Thrombin and GPIbα – Structure and Function
The interaction between thrombin and GPIbα has been highly studied in the last 30 years.
Initial mutagenesis studies had localized thrombin binding sites on GPIbα to the sulfatedtyrosine rich anionic peptide (STRAP) region of the protein.112 On the other hand, until recently
the binding site of GPIbα on thrombin was heavily debated. It has been demonstrated in several
instances that such interaction causes allosteric changes in thrombin activity and specificity.79,80
Earlier competitive studies with exosite 1 ligands such as hirudin, fibrinogen and
thrombomodulin, showed that these ligands compete with GPIbα-thrombin interaction.80,113
Furthermore, synthetic anionic peptide of GPIbα 269-287 was earlier found to interact with
thrombin exosite 1 and enhance catalytic efficiency of thrombin towards small chromogenic
substrates.114 However, such synthetic peptides were not revealed to have any sulfated tyrosines
and there was no mention of sulfation step during their synthesis. In 2001, affinity studies on
thrombin mutants revealed that GPIbα binds to exosite 2 mainly involving residues: R93A (22fold defect), R97A (8-fold defect), R101A (13-fold defect), R233A (29-fold defect), K236A (21fold defect), K240A (5-fold defect), and for the triple mutant R233A/K236A/Q239A (31-fold
defect), while the Q239A and R67A forms did not show any significant affinity change.115
Additional mutational studies and competition studies with low molecular weight heparin further
demonstrated involvement of exosite 2 and also that binding of GPIbα to thrombin exosite 2
induced an allosteric change in the activity of thrombin.79
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To further complicate the scenario, two separate groups released crystal structures in July
2003 having multiple thrombin molecules bound to GPIbα (Figure 11).116,117 In these crystal
structures both exosite 1 and 2 binding to GPIbα was demonstrated and multiple thrombin
molecules were found to bind to GPIbα. However, exosite 2-GPIbα interface was more similar as
compared to residues involved in the exosite 1-GPIbα interface (Figure 11 and 12), suggesting
that exosite 2 interaction was possibly tighter.118 It was suggested that thrombin could possibly
also act as an adhesion molecule between platelets due to the fact that multiple thrombin
molecules could bind in different poses. Further modeling suggested that GPIbα-thrombin
interaction could be pH dependent and that binding to the STRAPs of GPIbα is likely to precede
the binding of the rest of the molecule to the LRR of GPIbα in a loose manner.119 However, two
recent publications showed that GPIbα binds to thrombin in 1:1 ratio in solution and that NMR
studies have demonstrated that only exosite 2 is involved.52,120 Furthermore, it was confirmed in
all above studies that the STRAP of GPIbα was essential for binding to thrombin.
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Figure 11. Comparison of two reported crystal structures of GPIbα and thrombin. (A) Shows the
individual crystal structures reported in PDB: 1OOK116 and 1P8V.117 (B) Shows the
superimposed crystal structures showing that thrombin exosite-2 interacts in reproducible
manner with the anionic peptide region of GPIbα. Image adapted from reference 118.118
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Figure 12. GPIbα interaction with thrombin exosite 2. (A) Interaction of STRAP found in GPIbα
with exosite 2 of thrombin. (B) A closer look shows how STRAP interacts with R126, K235,
K236, R233, R101, R93 and K240 of thrombin exosite 2.
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The physiological consequences of binding of thrombin to GPIbα are diverse. On one
hand, binding of thrombin to GPIbα can result in activation of platelets; a pro-thrombotic
effect,121 while on the other hand, GPIbα binding to thrombin causes allosteric inhibition of
thrombin’s catalytic efficiency for fibrinogen cleavage, an anticoagulant effect.79,80 Additionally,
isolated STRAPs from GPIbα (268-282) have been shown to bind to exosite 2 and allosterically
inhibit thrombin-mediated activation of factor VIII.82 Reviewing the two peptide studies above, it
is possible that sulfated tyrosines could direct GPIbα towards exosite 2 binding, while the nonsulfated forms could bind via exosite 1. Even hydrogen-deuterium exchange (HDX) studies
show that exosite 2 binding of GPIbα reduces HDX for sites distant from the binding interface
suggesting long range conformational changes.120
Platelet activation by thrombin involves proteolytic and non-proteolytic mechanisms, and
intact GPIbα facilitates the platelet response to low but not high doses of thrombin.96 GPIbα acts
as a cofactor for thrombin-dependent activation of PAR-1 as well as GPV.81,122 However, even
active site blocked thrombin can activate platelets using GPIbα when PAR-1 or GPIIb/IIIa is
inhibited, suggesting alternate routes of thrombin-GPIbα activation of platelets.123 Such
mechanisms can possibly explain why active site thrombin inhibitors and anti-platelet regimens
do not completely abrogate thrombosis/restenosis in patients. Targeting the interface of the
interaction could provide a more useful antithrombotic.
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1.9 Structure and Function of Factor XIa – An Emerging Target for Prophylactic
Anticoagulation
An ideal target for prophylactic anticoagulant therapy would be able to segregate
hemostasis and thrombosis functions. Factor XIa (fXIa) is one such target that is believed to
predominantly affect thrombus formation, rather than hemostasis. Although, the crystal structure
of the entire apo-enzyme fXIa has not been resolved, there exists a crystal structure of the
zymogen form of the enzyme fXI.124 Additionally, there exist several crystal structures of the
catalytic domains, which can help shed light on the structure of the apo-enzyme in its active
conformation.
Structurally, factor XI is a unique 160kDa serine protease, which differs from vitamin-K
dependent proteases in being a dimer of identical subunits (Figure 13A).125 Each subunit consists
of 4 apple domains (A1, A2, A3 and A4) composed of 90-91 amino acids at the N-terminus, and
a trypsin-like catalytic domain (CD) at the C-terminus, which sits on top of the apple domains in
a cup and saucer arrangement. The two subunits of fXI are held together by an interchain
disulfide bond, Cys321-Cys321.124,126,127 In the intrinsic pathway, factor XIIa (fXIIa) activates the
zymogen factor XI (fXI) by catalyzing the cleavage of the peptide bond, Arg369-Ile370 on each
subunit. Following activation, the enzyme is believed to undergo a dramatic shape change
leading to a reorientation of the structure such that the catalytic domains of the two subunits
come closer together (Figure 13B).128 Factor XIa has been shown to bind several biological
macromolecules including high molecular weight kininogen,129 thrombin,130 heparin,131-134 factor
IX,135-137 platelet glycoprotein Ib,138,139 apolipoprotein E receptor 2140 via allosteric sites (Figure
13C). Allosteric modulators similar to its protease counterpart thrombin could yield controlled
anticoagulant therapy.
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A

B

C

Figure 13. Structure of factor XI and XIa. (A) The topology of the factor XI dimer with catalytic
domain colored in red, and the four apple domains (gray, blue, orange and yellow) arranged in
a cup and saucer arrangement with the Cys321 disulfide bond linking the two sub-units.124 (B) A
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factor XIa model created on the basis of small-angle x-ray scattering and electron microscopy
data in which the two catalytic domains (cat and cat’ in cyan and gray) come close to each
other.128 (C) The factor XI dimer from two perspectives rotated 90° highlighting the binding
locations of different modulators of factor XI.126 Sites for ligand binding are thrombin in red (T),
high molecular weight kininogen in green (HK), GPIbα in black, heparin binding sites in blue
(H1 and H2), factor IX in orange (FIX). In purple is shown the activation loop (AL) cleavage site
(Arg360-Ile370) and the active site (AS) catalytic triad (Ser557, Asp462, and His413). Note: All
images for this figure are taken directly from literature or corresponding supplementary
information.

Functionally, factor XIa activates factor IX (fIX), which in turn activates the downstream
coagulation cascade. Thus, it ultimately contributes to the formation of a stable clot.141 Apart
from fXIIa, fXI can undergo autoactivation. More interestingly, it can be activated by thrombin
generated in small amounts in the early stages of coagulation in a process that is independent of
fXIIa.127,142 In such a way, fXIa is responsible for rapidly regenerating thrombin which is
essential for maintaining fibrin clot integrity, thus providing a positive feedback for
coagulation.143 fXIa also enhances activation of thrombin-activable fibrinolysis inhibitor (TAFI),
which is known to make clots less sensitive to fibrinolysis.144 Thus, targeting this upstream
protease would leave the extrinsic and common pathways of the coagulation cascade intact,
thereby preventing excessive bleeding.145
Several studies have confirmed fXIa is a useful target for development of prophylactic
anticoagulant therapy:146 for example, fXI-null mice, in comparison to wild type (WT) mice
were clearly less susceptible to arterial and venous thrombosis when thrombosis was induced by
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FeCl3,147 or laser injury models.148 This demonstrates that blocking fXIa could yield potential
antithrombotic treatment. Additionally, fXI-deficient mice are healthy, thereby demonstrating
that inhibition of the protease would result in safe anticoagulation.149 Another study involving
neutralizing antibodies against fXI have also demonstrated a reduction in thrombus formation in
rabbits.150 Even in humans, the natural deficiency of fXI (hemophilia C) (prominent in
Ashkenazi Jews in Israel) results in a very benign bleeding phenotype compared to other
hemophilia.151-154 This provides strong support that fXIa inhibition could provide safe
anticoagulant modality. Recent reports have also linked fXI with inflammation. Thus inhibition
of fXIa could prove useful in its treatment as well.155-157

1.10 Current Thrombin, GPIbα and Factor XIa Inhibitors
The well accepted concept that inhibition of thrombin would result in efficacious
anticoagulation to prevent several cardiovascular diseases has been around for more than 3
decades.158 On the other hand, the concept of inhibition of GPIbα to provide efficacious
antithrombotic drugs is only surfacing recently.159 This has been largely due to the fact that
GPIbα is a transmembrane protein, and technological limitations have limited the study of this
target protein until recently.
Ever since heparin’s discovery in 1916 by Jay Mclean, it has been a widely used
antithrombotic drug.160 Polymeric heparin which is a glycosaminoglycan, is the most anionic
macromolecule found within the body and is highly decorated with carboxylic acid and sulfate
groups (Figure 14).161 It performs a number of interactions and is known to accelerate serpinmediated inhibition of thrombin by: antithrombin, heparin cofactor II, protein C inhibitor and
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protease nexin-1.162 Yet full length heparin suffers from several drawbacks such as difficulty in
dosing,

bleeding

complications

and

severe

side

effects

such

as

heparin-induced

thrombocytopenia (HIT).163 Smaller versions of heparin such as low molecular weight heparin
(LMWH) and heparin pentasaccharide (fondaparinux) seem to be safer. However, such smaller
versions cannot participate in the bridging mechanism required to inhibit thrombin and therefore
are only capable of inhibiting factor Xa.72 As a consequence, subcutaneous LMWHs and
fondaparinux take time to achieve anticoagulation and the therapeutic range is difficult to predict
in order to treat arterial thrombosis.164
Another traditional anticoagulant, which has been used for more than 50 years is warfarin
(Figure 14).165 Mechanistically, warfarin acts as an inhibitor of vitamin K epoxide reductase
enzyme, by antagonizing vitamin K. This enzyme is crucial for the generation of the γcarboxyglutamic acid residues (GLA) which is an important post-translational modification in
several proteases of the coagulation cascade including thrombin. The GLA domains of
coagulation proteases help anchor them on cell surface membranes.166 The advantage of warfarin
as a therapy is its ease of synthesis and oral bioavailability. However, warfarin therapy suffers
from several food-drug as well as drug-drug interactions and can cause severe bleeding side
effects. Consequently, warfarin therapy requires constant monitoring due to unpredictable
pharmacokinetics and inter-patient variability.167
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Figure 14. Structures of anticoagulants that have been introduced to the clinic including,
heparin, warfarin, factor Xa inhibitors apixaban and rivaroxaban, thrombin inhibitors:
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argatroban, melagatran, ximelagatran, dabigatran and dabigatran etexilate, and the hirudin
derivatives: hirudin, lepirudin, desirudin, and bivalirudin. The image of the hirudin derivatives is
taken directly from reference 168. 168

Around two decades ago, a new class of peptide-based thrombin inhibitors was
discovered from medicinal leeches, Hirudo medicinalis.169 This peptide was called hirudin
(Figure 14), and was found clinically useful in patients who suffer from heparin-induced
thrombocytopenia. Hirudin inhibits thrombin by a dual binding site mechanism, where an
anionic C-terminal binds to exosite 1 while the N-terminal interacts with the active site to abolish
catalytic activity. This dual binding capability makes hirudin a highly specific inhibitor of
thrombin (Ki = 20 fM). Several derivatives of hirudin such as lepirudin, desirudin, bivalirudin
were also developed and clinically used (Figure 14). Yet, being a peptide-based drug, these
therapies suffered from quick proteolysis within the body and variation in clearance in patients
with kidney disorders. These issues lead to dosing complications. Additionally, such molecules
are difficult to produce on a large scale and are costly. Hence they can only be usefully as an
alternative to UFH in patients with HIT.170
Several novel small molecule anticoagulants based on the active site inhibitors of
thrombin and factor Xa have emerged in the market in the past decade (Figure 14). These include
thrombin inhibitors such as argatroban, melagatran (and its prodrug ximelagatran), dabigatran
(and its prodrug dabigatran etexilate); and factor Xa inhibitors like apixaban and
rivaroxaban.171,172 Out of these ximelagatran was taken off the shelf due to potential
hepatotoxicity.173 While these drugs have an improved safety profile of anticoagulant therapy,
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they are still not completely devoid of bleeding complications.174 This is understandable as these
drugs target the active site of important coagulation proteases which results in complete knockout of these enzyme activities. Alternatively allosteric inhibitors are gaining importance in order
to modulate coagulation protease activity in a more fine-tuned manner, with possibly better
safety profiles.3
In contrast to thrombin, no drug has reached the clinic which specifically targets platelet
GPIbα-protein interactions. However, targeting the platelet GPIb complex is thought to be a
potential route for development of antithrombotic drug development.175 Several antibodies, snake
venom proteins, mutant thrombin molecules and peptides have been researched to bind to GPIbα
and inhibit its various physiological functions.175 Such research has shown promise in in-vitro,
ex-vivo and in-vivo animal models, that targeting GPIbα can yield efficient antithrombotic
without causing undue bleeding problems.

However, only recently has there been any

development of small molecules targeting specific protein-protein interactions involving GPIbα,
such as the GPIbα-VWF interaction.176 To date, heparin is the only clinically used drug which
has been shown to prevent thrombin-mediated platelet aggregation and activation, by targeting
exosite 2 of thrombin and preventing GPIbα-thrombin interaction.177
Similarly, factor XIa also has no established clinically used drug. Yet there is significant
data to support the hypothesis that targeting factor XIa would provide a useful prophylactic
anticoagulant that would possibly have fewer anticoagulant side effects.145
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Chapter 2: Rationale
2.1. Background
The presence of thrombosis in several cardiovascular disorders stimulates an
anticoagulant market which has grown to at least $10 billion.3 The anticoagulant market is
dominated by the century old heparin and its derivatives. In the past decade, there has been an
advent of novel active-site inhibitors of factor Xa and thrombin. Yet, there is not significant
improvement of safety profiles of such drugs and long term side effects still remain questionable.
The active site of serine proteases is highly conserved among various enzymes within the
body.34 Due to this fact, targeting the active site specifically of a particular enzyme proves
challenging and non-specific interactions could lead to long term toxicities. Such toxicity could
possibly go unnoticed in short-term clinical trials. In comparison, allosteric sites on enzymes are
relatively less conserved and offer a unique topographical identity, unlike active sites.97
Furthermore, allosteric inhibition could possibly result in suppression of activity without
complete blockage, resulting in safer anticoagulants with fewer bleeding complications. We have
designed synthetic sulfated β-O4 lignin (SbO4L) as allosteric inhibitors of thrombin based on
two elements (Figure 15):
1. Structural resemblance to chemoenzymatically synthesized lignins
2. Mechanistic resemblance to STRAP found in GPIbα
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Figure 15. Rationale behind the creation of synthetic sulfated β-O4 lignin (SbO4L) polymer as a
structural mimic of chemoenzymatically synthesized sulfated lignins (CDSO3, FDSO3, SDSO3)
and mechanistic mimic of the STRAP of GPIbα.

2.2. Structural Resemblance to Direct Exosite 2 Binding Inhibitors
As seen earlier thrombin exosite 2 has been linked to modulation of active site function.
Yet not all exosite 2 ligands induce a functional change in the catalytic activity of the enzyme.
For example, heparin, which is the primary physiologic molecule that binds exosite 2 of
thrombin, does not affect the catalytic efficiency alone, but acts as a cofactor for antithrombin
III.72 On the other hand, a number of physiologic ligands show modification of thrombin activity
or specificity. Due to the presence of such an allosteric network, it is not impossible to fathom
the probability of allosteric inhibitors of thrombin which target exosite 2 directly. In general, it is
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observed that sulfated aromatic scaffolds like sulfated tyrosines are capable of inhibiting
thrombin via exosite 2-mediated allosterism.
Overall, two pathways of research have emerged over the years to target thrombin
exosite-2. One pathway involves the synthesis of DNA and RNA aptamers which inhibit
thrombin by binding to exosite 2 of thrombin. Aptamers are small sequences of nucleic acids that
are capable of binding a target protein or nucleic acid with high affinity.178 Using SELEX
(Systematic Evolution of Ligands by Exponential Enrichment), the first aptamer based thrombin
inhibitors were obtained by Bock et al., which was a 15-mer (TBA-15).179 This aptamer was
found to bind at exosite 1 of thrombin.68 However later, a 29-mer was identified (DNA 60-18)
which binds at the heparin binding exosite 2 with 20 to 50-fold higher affinity compared to TBA15.77 The phosphate groups of the aptamers are capable of binding the electropositive residues on
exosite 2 to enhance affinity, while the aromatic nature of the purines and pyrimidines can mimic
the aromaticity of sulfated tyrosines to induce allosterism. Aptamer technology had gained a lot
of popularity over a decade ago and had even reached Phase I clinical trials.3 However, due to
instability of the aptamers, the molecules have a short in vivo half-life (~2 min), requiring high
doses of aptamers.180 It is observed, that conformational stability of the aptamers is highly
dependent on the cation it chelates.181 Current research is on-going to improve aptamer stability.
However, the aptamer technology remains elusive for therapeutic value and has greater potential
in developing diagnostic biotechnologies in the form of nanosensors to detect levels of thrombin
and other biomedical applications.181
The second approach was taken by our laboratory to mimic the sulfation patterns of
heparin, while utilizing relatively hydrophobic aromatic lignins in order to induce inhibition of
thrombin. The first generation lignins were synthesized utilizing chemoenzymatic methods in
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order to form dehydropolymers (DHPs) of caffeic acid (CD), sinapic acid (SD) and ferulic acids
(FD) using horse radish peroxidase enzyme.182 Lignin synthesis via chemoenzymatic synthesis
leads to heterogeneity in the intermonomeric linkages. Such synthesis yields predominantly β-O4
type linkage, followed by β5 type linkage. These DHPs were then sulfated to give the respective
sulfated lignins CDSO3, SDSO3 and FDSO3. All sulfated lignins were found to be potent
inhibitors of thrombin in nanomolar concentrations utilizing a direct allosteric mechanism which
involves exosite 2.183 Such lignins were also potent in ex vivo blood and plasma assays.184
However, lack of homogeneity in intermonomeric linkage results in a mixture of diverse
scaffolds, which was not specific for only thrombin inhibition, as it was found that these sulfated
lignins were capable of inhibiting other heparin binding serine proteases found in the body such
as plasmin, factor XIa, factor Xa, cathepsin G and human leukocyte elastase with relatively good
potency in nM-range (Table 1).185,186 The pursuit of identifying possible small molecule
inhibitors from these parent lignins involved the exploration of selective synthesis of the β5 type
linkage in the synthesis of benzofuran monomers, dimers and trimers.187-189 These studies
revealed that exosite 2 of thrombin can be targeted using small molecules with low sulfation
levels, and that there were different sub-pockets in exosite 2 which can possibly inhibit thrombin
allosterically.
What was largely unexplored was the β-O4 type intermonomeric linkage, which is in
fact, the most predominant linkage found in chemoenzymatically synthesized lignins. Hence the
rationale exists that the development of a chemically synthesized, homogenous SbO4L lignin
polymer would likely contain a more potent, and possibly a more selective derivative of the
DHPs, which could inhibit thrombin via an exosite 2-driven allosterism.
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Table 1. Cross reactivity of chemoenzymatically synthesized lignins CDSO3, FDSO3 and
SDSO3 against heparin binding serine proteases shows potent IC50. 185,186
Proteases

CDSO3*

FDSO3*

SDSO3*

Cathepsin G 232 ± 10

91 ± 7

105 ± 7

Factor XIa

22 ± 2

105 ± 11

176 ± 11

HLE

11 ± 2

9±2

17 ± 1

Factor Xa

34 ± 5

74 ± 8

121 ± 26

Plasmin

240 ± 30

760 ± 20

1290 ± 60

Thrombin

18 ± 2

29 ± 2

94 ± 4

*(all concentrations are in nM)

2.3. Mechanistic Resemblance Inspired from STRAP found in GPIbα
As reviewed earlier (Chapter 1: Introduction), sulfated tyrosine rich anionic peptide
(STRAP) region found in GPIbα is known to be crucial for the interaction between exosite 2 of
thrombin and GPIbα. The physiological consequences of this interaction are both pro-thrombotic
as well as anticoagulant. Thus, it would seem that nature has engineered a self check mechanism
in order to control hemostatic and hemorrhaging factors utilizing this STRAP. By mimicking the
STRAP using an aromatic sulfated scaffold like that found in SbO4L, we could possibly induce
allosteric anticoagulant activity via inhibition of thrombin catalytic activity, while additionally
obtaining a competitive antiplatelet activity by blocking the interaction of thrombin with platelet
GPIbα. To date, no synthetic molecule has achieved this dual mechanism.
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2.4. Questions to be answered
There are several questions which needed to be answered in a sequential and systematic
manner. These are as follows:
1. Can we create a chemically synthesizable sulfated lignin with only β-O4 type
intermonomeric linkage (SbO4L)?
2. Can such molecules induce allosteric inhibition of thrombin by binding to exosite
2?
3. Can such a molecule compete with GPIbα?
4. Will such a molecule be selective for thrombin compared to the parent sulfated
lignins?
5. Will such a molecule resemble the STRAP of GPIbα in its binding and allosterism
mechanism?
6. Will the inhibition of thrombin translate to potent anticoagulation?
7. Will the competition with GPIbα translate to potent anti-platelet effects?
8. Is the overall antithrombotic effect translatable to ex-vivo whole blood assays and
in vivo in mice thrombosis assays?
These studies will not only help identify a new class of antithrombotics but also shed
light on possible interplay between the coagulation and platelet aggregation/activation pathways
of hemostasis. Additionally, such molecules will highlight the applicability of STRAP-mimetics
to target important protein-protein interactions which could result in molecules with varying
functions.
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Since, the β-O4 type intermonomeric linkage showed greater selectivity for thrombin in
our studies, we rationalized that small molecules of the β-5 type linkage such as the benzofuran
dimers and trimers, could possibly be more potent inhibitors for other coagulation cascade
proteins. In particular, factor XIa is gaining wide importance as a potential target for developing
prophylactic anticoagulants that could prevent cardiovascular diseases (as discussed in the
Chapter 1: Introduction). We therefore sought to screen and characterize the inhibition of a
library of sulfated small molecules and in particular the sulfated benzofurans for factor XIa
inhibition activity. We have attempted to address questions regarding its mechanism and
plausible binding site via competition assays, recombinant proteins and molecular modeling.
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Chapter 3: Synthesis and Biochemical Analysis of Sulfated β-O4 Lignin (SbO4L) Polymer
3.1 Introduction
Recently, our laboratory designed the first few examples of exclusively allosteric
coagulation enzyme inhibitors. These include the sulfated LMW lignins and sulfated
benzofurans.182-185,187,188,190 Sulfated LMW lignins were originally designed to mimic the
allosteric interaction of heparin with antithrombin, a key regulator of coagulation.182,191 Yet,
detailed studies pointed to direct inhibition of thrombin as the major mechanism of
action.183,186,190 Interestingly, these molecules were found to bind in the heparin-binding site of
the enzyme and induce allosteric inhibition.183 However, being chemo-enzymatically
synthesized, these sulfated LMW lignins were polydisperse with respect to their inter monomer
linkages, with various possibilities such as β-O4, β-5, β-β, 5-5 and others.191 As a result of this
hetereogeneity, they lacked selectivity and were capable of inhibiting serine proteases other than
thrombin including factor Xa, factor XIa, human leucocyte elastase (HLE), plasmin, and
cathepsin G (Table 1).186 Hence, further anticoagulation studies were not pursued for these
molecules.
We rationalized that a chemically synthesized molecule with greater homogeneity in the
inter-monomeric linkage could possibly provide a more selective inhibitor. Further, such a
molecule could possibly target exosite 2 in a manner similar to GPIbα. In this work, we report on
the development of a sulfated β-O4 lignin (SbO4L), a chemically synthesized lignin, which
exhibits highly selective and potent inhibition of human thrombin and plasmin in comparison to
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other serine proteases due to its homogeneity in its inter-monomeric linkages compared to parent
lignins. Furthermore, SbO4L shows lower potency for thrombomodulin bound thrombin,
indicating that it could be useful in directing thrombin to more anticoagulant state. SbO4L also
inhibits thrombin in a mechanism which is independent of antithrombin III. It inhibits thrombin
through an allosteric process by binding in exosite 2. Mutagenesis data suggests that SbO4L
binds at a site similar to the GPIbα-STRAP on the exosite 2 of thrombin. Additionally, SbO4L
inhibition of thrombin is quantitatively and rapidly reversed by protamine. The work here
demonstrates that small sulfated aromatic molecules could possibly be used to target the GPIbαSTRAP binding site on the exosite 2 of thrombin for a novel mechanism of modulation of
coagulation protease thrombin.

3.2

Experimental

Materials
Human plasma proteases, thrombin and factors Xa, IXa, XIa and VIIa, recombinant tissue factor
(rTF), activated protein C, human protein C and human plasma antithrombin were from
Haematologic Technologies (Essex Junction, VT). Cathepsin G, chymotrypsin, kallikrein,
trypsin,

pancreatic

porcine

elastase

(PPE),

protamine

sulfate,

recombinant

human

thrombomodulin, bovine serum albumin and argatroban monohydrate were obtained from Sigma
Aldrich (St. Louis, MO). Recombinant glycoprotein Ibα (GPIbα) was obtained from R&D
Systems (Minneapolis, MN). Human leucocyte elastase (HLE) was from Elastin Products
Company (Owensville, MO). Chromogenic substrates Spectrozyme TH, Spectrozyme FXa,
Spectrozyme FIXa, Spectrozyme VIIa, Spectrozyme PCa, Spectrozyme PL, and Spectrozyme
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CTY were obtained from Sekisui Diagnostics (Stamford, CT). Substrates N-succinyl-Ala-AlaPro-Phe-pNA, N-(methoxysuccinyl)-Ala-Ala-Pro-Val-pNA, and N-succinyl-Ala-Ala-Ala-pNA
were obtained from Sigma Aldrich (St. Louis, MO) and S-2266, S-2222 and S-2366 were
obtained from Diapharma (West Chester, OH). Stock solutions of proteins were prepared in 20
mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2, and 0.1 % polyethylene
glycol (PEG) 8000 (thrombin and factor XIa) or 20 mM sodium phosphate buffer, pH 7.4,
containing 0.1 mM EDTA and 0.1% PEG8000 (factor Xa). Factor VIIa stock solutions of
proteins were prepared in 25 mM HEPES buffer, pH 7.4, containing 100 mM NaCl and 5 mM
CaCl2, while factor IXa stock solutions were prepared in 100 mM HEPES buffer, pH 8.0
containing 100 mM NaCl and 10 mM CaCl2. Porcine unfractionated heparin (MW 15000) was
purchased from Sigma (St. Louis, MO). HirP, a Tyr63-sulfated hirudin-(54-65) peptide labeled
with 5-(carboxy)fluorescein, i.e., [5F]-Hir[54-65](SO3-), was a gift from the Bock laboratory at
Vanderbilt University. Recombinant thrombin mutants were a gift from Dr. Alireza Rezaie (Saint
Louis University, MO). All other chemicals were analytical reagent grade from either Sigma
Aldrich (St. Louis, MO) or Fisher (Pittsburgh, PA) and used without further purification.
Synthesis of SbO4L
For synthetic scheme see Figure 16, Pg. 69.
4-(tert-butyldimethylsilyloxy)-3-methoxybenzaldehyde (2): In a 500ml round bottom flask add
20 g (1 eq) of vanillin (1) in 120 ml of dichloromethane. To this mixture add 45.8 ml (3 eq) of
diisopropyl ethyl amine (DIPEA). Add 23.8 g (1.2 eq) of tert-butyldimethylsilane chloride
(TBDMSCl). Stir overnight under nitrogen. Add 100 mL water to quench the reaction and dilute
with 300 ml dichloromethane. Separate out the organic layer. Wash the aqueous layer with 500
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ml x 2 dichloromethane. Collect the organic layer and dry with sodium sulfate, filter and
evaporate using rotary evaporator. Perform a normal silica column by first washing with hexanes
followed by a gradient elution up to 10% ethyl acetate (EtOAc) in hexanes to obtain pure
compound 2 (35 g, yield = 99%).
1

H-NMR (CDCl3): 9.85 (CHO) (s, 1 H), 7.39-7.40 (C2-H) (d, 1 H), 7.35-7.37 (C6-H) (m, 1 H) ,

6.95-6.97 (C5-H) (d, 1 H), 3.87 (-OCH3) (s, 3 H), 1.01 (TBDMS-t-butyl) (s, 9H), 0.19 (TBDMSMe) (s, 6H).
13

C-NMR (CDCl3): 190.95, 151.65, 151.35, 130.97, 126.17, 120.71, 110.18, 55.44, 25.59, 18.49,

-4.56
ethyl 3-(4-(tert-butyldimethylsilyloxy)-3-methoxyphenyl)-3-oxopropanoate (3): In a 500 ml
round bottom flask, take 7.5 g of 2 and add a stir bar. To this add 250 ml dichloromethane. Flush
nitrogen gas through the container and place on ice bath. Add 400 mg (0.05 eq) of niobium (V)
chloride (NbCl5) as catalyst, which should be a fine, yellow colored powder. Seal the flask with a
rubber stopper and parafilm or PTFE tape. Place a venting needle in the rubber stopper and
slowly add 4.9 ml (1.4 eq) of ethyl diazoacetate solution (containing ≤ 15% dichloromethane)
with care using a syringe. The reaction will effervesce vigorously for a few minutes with the
release of nitrogen gas. Let the reaction mixture come to room temperature and stir for 3 hours.
Monitor the reaction using TLC. Quench the reaction by adding 5 ml water and stir the flask
open for 10 minutes. The solution will turn light yellow and a precipitate of NbCl 5 will be
obtained. Filter the solution through a short pad of celite to remove the catalyst, and wash the
celite pad with 2 x 200 ml dichloromethane. Add 100 ml water and extract the organic phase.
Wash the aqueous layer with 2 x 200 ml dichloromethane. Collect the organic layer and dry over
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sodium sulfate, filter and evaporate using rotary evaporator making sure that the temperature
does not exceed 35°C. Remove any unreacted ethyl diazoacetate by evaporation on high vacuum
overnight. The pure product 3 can be isolated using normal silica column with gradient elution
up to 10% EtOAc in hexanes to give a pale-yellow to colorless oil (8.5 g, yield = 86%).
1

H-NMR (CDCl3): 7.53 (C2-H) (d, 1 H), 7.44-7.46 (C6-H) (m, 1 H) , 6.88-6.90 (C5-H) (d, 1 H),

4.19-4.25 (-OCH2CH3) (q, 2 H), 3.95 (α-CH2) (s, 2 H), 3.87 (-OCH3) (s, 3 H), 1.25-1.28 (OCH2CH3) (t, 3 H), 1.01 (TBDMS-t-butyl) (s, 9H), 0.2 (TBDMS-Me) (s, 6H).
13

C-NMR (CDCl3): 191.14, 167.73, 151.23, 150.70, 130.19, 123.16, 120.33, 111.41, 61.36,

55.47, 45.79, 25.59-25.70, 18.49, 14.08, -4.57.
ethyl 3-(4-hydroxy-3-methoxyphenyl)-3-oxopropanoate (4): Take 6.3 g of 3 in a 250 ml round
bottom flask and add 10 ml dimethylformamide (DMF) to it. Add 3.1 g (3 eq.) of potassium
fluoride (KF) and catalytic quantity of acetic acid (0.01 ml). Stir the reaction vessel for 12 hours.
Add 50 ml mildly-acidified water to quench the reaction. Extract the aqueous layer with 250 x 3
washes of ethyl acetate. Collect the organic extracts, dry over sodium sulfate and filter.
Evaporate the filtrate using rotary evaporator. The product 4 is purified using normal silica
column with step gradient elution up to 70% EtOAc in hexanes in 10% increments over two
column volumes (3.98 g, yield = 94%).
1

H-NMR (CDCl3): 7.55-7.56 (C2-H) (d, 1 H), 7.50-7.52 (C6-H) (m, 1 H) , 6.95-6.98 (C5-H) (d,

1 H), 6.20 (-OH) (s, 1 H), 4.20-4.25 (-OCH2CH3) (q, 2 H), 3.96 (α-CH2) (s, 2 H), 3.95 (-OCH3)
(s, 3 H), 1.25-1.29 (-OCH2CH3) (t, 3 H).
13

C-NMR (CDCl3): 190.96, 167.74, 151.00, 146.80, 129.06, 124.17, 113.98, 110.11, 61.42,

56.09, 45.69, 14.08.
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ethyl 2-bromo-3-(4-hydroxy-3-methoxyphenyl)-3-oxo-propanoate (5):

In a 250 ml round

bottom flask, take 1.2 g of compound 4. Place the flask on an ice bath and add 40 ml of
dichloromethane and then 1.17g (1.05 eq) bromodimethylsulfonium bromide (BDMS) as a
yellow powder. Stir the reaction mixture till it reaches room temperature (30 mins). Add 50 ml
water and another 50 ml of dichloromethane. Separate the organic layer. Wash the aqueous layer
with 3 x 50 ml dichloromethane. The collected organic layer is dried over sodium sulfate, filtered
and evaporated using rotary evaporator taking care that the temperature does not exceed 35°C.
The pure monomer 5 is obtained without any further purification (1.55g, yield = 97%).
1

H-NMR (CDCl3): 7.58-7.60 (C2-H, C6-H) (m, 2 H) , 6.97-6.99 (C5-H) (d, 1 H), 6.23 (-OH) (s,

1 H), 5.65 (α-CHBr) (s, 1H), 4.27-4.33 (-OCH2CH3) (q, 2 H), 3.98 (-OCH3) (s, 3 H), 1.26-1.30
(-OCH2CH3) (t, 3 H).
13

C-NMR (CDCl3): 186.64, 165.37, 151.51, 146.90, 126.14, 124.70, 114.12, 111.05, 63.23,

56.16, 46.20, 13.90.
β-Keto-Ester Polymer (6): In a flask containing the monomer 5 (0.97 g) (or other appropriate
monomer) in anhydrous DMF (5 mL), anhydrous K2CO3 (0.58 g) was added and stirred under
nitrogen. After 24 h the reaction mixture was poured onto ice-water mixture (120 ml) and the pH
adjusted to ~2.5 with 2M HCl. The precipitated polymer 6 was filtered, washed with water and
lyophilized to remove moisture. (≈700 mg per reaction)
NMR characterization showed the following corresponding broad peaks for 1H-NMR (DMSOd6): 7.46-7.78 (C2-H and C5-H), 6.91-7.14 (Cβ-H), 6.52-6.66 (C6-H), 4.19-4.20 (-OCH2CH3),
3.79-3.81 (-OCH3), 1.12-1.22 (-OCH2CH3).
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13

C-NMR (DMSO-d6) 188.53, 189.08 (Cα), 165.81,166.02 (Cγ), 153.16, 150.93, 149.48, 149.01,

147.64, 128.33, 125.51, 124.75, 123.73, 115.17, 114.08, 113.91, 113.09, 112.51, 112.30
(aromatic carbons), 78.54, 78.37 (Cβ), 61.80, 61.67 (-OCH2CH3), 55.78, 55.58 (-OCH3), 13.77
(-OCH2CH3).
Reduced Polymer (7): 600 mg of solid 6 was suspended in methanol (10 ml) followed by careful
addition of NaBH4 (683 mg). The mixture was gradually heated to 50°C as it turned clear, and
was stirred for 24 h. The solution was then neutralized with acetic acid and poured into 0.5M
HCl (200 mL) to precipitate the reduced crude polymer 7, which was isolated by filtration
through sintered glass funnel, washed with water and lyophilized overnight. Dissolution and
preferential precipitation using 1,4-dioxane and diethyl ether helped remove low molecular
weight chains of the polymer and precipitate the high molecular weight chains. The precipitated
pure reduced polymer 7 was filtered and dried using vacuum. (≈150 mg per reaction)
NMR characterization showed the following corresponding broad peaks for 1H-NMR (DMSOd6): 4.75 (Cα-H), 4.28 (Cβ-H), 3.20-3.71 (Cγ-H and –OCH3), 7.02 (C2-H), 6.94 (C5-H), 6.85
(C6-H).
13

C-NMR (DMSO-d6): 70.8, 71.4 (Cα), 83.6, 84.4 (Cβ), 59.8, 59.9 (Cγ), 55.4 (-OCH3), 134.7-

135.0 (C1), 111.3-111.7 (C2), 148.9 (C3), 146.7-147.0 (C4), 114.5-115.0 (C5), 119.4-119.7
(C6).
SbO4L: 50 mg of the reduced polymer 7, so obtained was made to react with triethylaminesulfur trioxide complex (600 mg) in anhydrous DMF (5 ml) at 65 °C for 24 h under reflux with
nitrogen. Following the reaction, 30% (w/v) aqueous sodium acetate (35 ml) was added and the
mixture stirred overnight to exchange the counter-ions of the sulfate groups. The solution was
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then poured into ice-cold ethanol (100 ml) to precipitate crude SbO4L, which was filtered and
washed twice with ice-cold ethanol (10 ml each) to remove any unreacted polymer. The
recovered solid was desalted using FloatALyzer G2 (Spectrum Labs) dialysis tubes (MWCO 0.10.5 KDa) or using ultra-filtration membrane (Ultracel YM1, NMWL 1,000 Da) with a stirred cell
under nitrogen at 30 psi (Millipore). Lyophilization of the retentate solution gave SbO4L.
(≈100mg per reaction)
NMR characterization showed the following corresponding broad peaks for 1H-NMR (DMSOd6): 6.77 (aromatic protons), 3.47-4.27 (Cα-H, Cβ-H, Cγ-H, -OCH3).
Elemental Analysis of SbO4L was carried out by Atlantic Mircolabs (Norcross, GA). Anal.
Calcd. for 22-mer SbO4L with 27 sulfate groups and associated with 24 waters is: C, 35.20; H,
3.85; S, 11.53. Found: C, 35.39; H, 4.15; S 11.54.
13

C-NMR could not give sufficient signal even at high concentrations of the sample, possibly due

to the presence of a wide variety of sulfation patterns and molecules of different chain lengths.
Extensive characterization of SbO4L was therefore carried out using size exclusion
chromatography and reversed-phase ion-pairing chromatography as described below.

Size Exclusion Chromatography of SbO4L
Size exclusion chromatography (SEC) was used to assess the molecular weight of the
synthesized SbO4L. For SEC analysis the Asahipak GS320 HQ column (Shodex, New York,
NY) was used with an isocratic flow rate of 0.7 mL/min of 0.1 N NaOH at pH 11.0. The
wavelengths of 280nm were used to detect the eluted polymer. Polystyrene sulfonate (PSS)
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standards were used for calibration purposes. The relationship between log of the molecular
weight and the elution volume (V) of the standards was linear with a R2 of 0.98. The
chromatograms obtained were sliced into 1000 time periods providing the MR for each period
and the corresponding intensity of absorbance (A) as the number of polymeric species with the
particular MR. These values were then utilized to calculate the number average molecular
weights (MN) and the weight average molecular weight (MW) and the polydispersity (P) using the
following equations:

(Eq. 1)

(Eq. 2)

(Eq. 3)

The peak molecular weight (MP) was calculated from extrapolation in the equation obtained from
the plot of log MW of PSS standards vs elution volume.

Reversed-Phase Ion-Pairing (RPIP) UPLC-MS
Three different batches of SbO4L synthesized were tested for similarity using a method of RPIPUPLC-MS which was adapted from previous report.192 Briefly, a Waters Acquity H-class UPLC
system equipped with a PDA detector and a tandem quadrupole (TQD) mass spectrometer was
used. A 1.7 μm BEH C18 column (2.1 mm X 150 mm) was used for fingerprinting, which
required 5 μl injection of SbO4L (400 μg/mL) at 30 ± 2 °C and a solvent system composed of
10% v/v acetonitrile-water (solvent A) and 75% v/v acetonitrile-water (solvent B). Both solvents
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contained n-hexylamine (25 mM) as an ion-pairing agent along with acid modifier formic acid
(0.1%). Resolution of SbO4L was achieved using a linear gradient from 0% to 100% solvent B
in 40 mins. Absorbance was monitored from 230-400 nm and the eluent was directly injected
into the mass spectrometer. ESI-MS detection conditions utilized positive ion mode with
capillary voltage of 4kV, cone voltage of 20 V, desolvation temperature of 350 °C and nitrogen
gas flow rate of 650 L/h. Mass scans were collected in the range of 500-2048 m/z within 0.6 s to
obtain the UPLC-MS fingerprints.

Direct Inhibition of Enzymes of the Coagulation Cascade
Inhibition of various coagulation cascade enzymes like thrombin, factors Xa, IXa, XIa and VIIa
by SbO4L was characterized using chromogenic substrate hydrolysis assays, as described
previously in literature.183,186 Briefly, a 10 µl aqueous solution of SbO4L was diluted with 930 µl
of an appropriate buffer in PEG20000-coated polystyrene cuvette. Plasmin, recombinant tissue
factor – factor VIIa inhibition was studied in a 96-well microplate format, as described below in
the section on heparin-binding serine proteases, except for measuring the activity over the full
range of SbO4L concentrations. The buffers used in these experiments were as follows: 20 mM
Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2 and 0.1 % PEG8000 for
thrombin, factor Xa and factor XIa; 100 mM HEPES buffer, pH 8, containing 100 mM NaCl and
10 mM CaCl2 for factor IXa; 25 mM HEPES buffer, pH 7.4, containing 100 mM NaCl and 5
mM CaCl2 for factor VIIa and factor VIIa–tissue factor complex; and 50 mM Tris-HCl, 150 mM
NaCl and 0.1% PEG8000, pH 7.4 for plasmin. This was followed by addition of a 10 µl solution
of the protease (stock concentrations used: 600 nM thrombin, 108 nM factor Xa, 152 nM factor
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XIa, 22.5 μM factor IXa, 4 μM factor VIIa). The enzyme and inhibitor were incubated at 37°C
for 10 minutes. In case of fVIIa–tissue factor complex, 10μl of 1:1 mixture of 266 nM factor
VIIa and 800 nM recombinant tissue factor was added as a complex. Following incubation, a 50
µl (or 5 μl in case of plasmin and recombinant tissue factor-VIIa assay) solution of chromogenic
substrate was rapidly added and the residual enzyme activity was measured from the initial rate
of increase in A405. The chromogenic substrates used were Spectrozyme TH (H-Dhexahydrotyrosol-Ala-Arg-p-nitroanilide),

Spectrozyme

cyclohexylglycyl-Gyl-Arg-p-nitroanilide),
nitroanilide),
nitroanilide),

Spectrozyme
Spectrozyme

FVIIa
PL

Spectrozyme

FXa
FIXa

(methoxycarbonyl-D(D-Leu-Phe-Gly-Arg-p-

(methanesulphonyl-D-cyclohexylalanyl-butyl-Arg-p-

(H-D-norleucyl-hexahydrotyrosol-lysine-para-nitroanilide).

Inhibition of factor XIa was studied using Spectrozyme FXa. Relative residual proteinase
activity at each concentration was calculated using the activity measured under otherwise
identical conditions, except for the absence of SbO4L. The IC50 was calculated from the
regressional analysis using logistic equation 4.
(Eq. 4)

In this equation Y is the fractional residual protease activity, i.e., the ratio of protease
activity in the presence of inhibitor to that in its absence; YM and Y0 are the maximum and
minimum fractional residual activities, respectively; IC50 is the concentration of the inhibitor that
results in 50% inhibition of enzyme activity; and HS is the Hill slope.
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Inhibition of Other Heparin-Binding Serine Proteases
Being highly sulfated, it is important to check if SbO4L can inhibit other proteases by mimicking
heparin. The direct inhibition of other heparin binding serine proteases was tested against SbO4L
using the chromogenic substrate hydrolysis assay (similar to above) using a 96-well microplate
format with conditions adapted from previous literature.186 Briefly, 5 μl of SbO4L (1.62mg/ml)
was diluted with 85 μL of an appropriate buffer at either room temperature or 37°C followed by
addition of 5 μl of the protease solution and incubation for 5 min. The activity of the protease
was assessed by addition of 5 μl of chromogenic substrate and measuring the initial rate of
increase in the absorbance at 405nm (<10% substrate consumption). The optimal assay
conditions for the heparin-binding serine proteases were as follows: 50 mM Tris-HCl, 50 mM
NaCl, pH 8.0, at room temperature for cathepsin G and Human Leukocyte Elastase (HLE); 20
mM Tris-HCl, 150 mM NaCl, 2 mM CaCl2 and 0.1% PEG8000, pH 7.5, at 37°C for Porcine
Pancreatic Elastase (PPE) and kallikrein; 50 mM Tris-HCl, 125 mM NaCl and 10 mM CaCl2, pH
8.0, at 37°C for activated protein C (APC); and 50 mM Tris-HCl, 150 mM NaCl and 0.1%
PEG8000, pH 7.4, at 37°C for trypsin and chymotrypsin. The enzyme concentrations used in
these experiments were 200 nM cathepsin G, 1 μg/ml HLE, 0.005 U/ml kallikrein, 0.0125 U/ml
PPE, 7 nM APC, 0.5 μg/ml chymotrypsin and 0.145 μg/ml trypsin. Chromogenic substrates used
were 1 mM N-succinyl-Ala-Ala-Pro-Phe-pNA (cathepsin G); 100 μM N-(methoxysuccinyl)-AlaAla-Pro-Val-pNA (HLE); 50 μM H-D-Val-Leu-Arg-pNA (S-2266) (kallikrein), 100 μM Nsuccinyl-Ala-Ala-Ala-pNA

(PPE);

200

μM

H-d-(γ-carbobenzoxyl)-Lys-Pro-Arg-pNA

(Spectrozyme PCa) (APC); 160 μM N-benzoyl-Ile-Glu-(-OR)-Gly-Arg-pNA (S-2222) (trypsin)
and 250 μM H-D-Ala-Pro-Phe-pNA (Spectrozyme CTY) (chymotrypsin). The percent residual
activity of the enzyme in the presence of the inhibitor with respect to control of no inhibitor was
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calculated from the initial velocity of the enzyme measured as the increase in the absorbance at
405nm as a function of time. Each assay was performed in duplicate.

Effect of SbO4L on Antithrombin III Inhibition
SbO4L inhibition of thrombin in the presence and absence of antithrombin III (ATIII) was
performed using a 96-well microplate assay that was adapted from previous reports.182 Briefly, in
180 µl of 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2 and 0.1%
PEG8000 a 5 µl aqueous solution of SbO4L was added. This was followed by addition of 5 µl of
thrombin to give a final concentration of 6 nM and 5 µl of antithrombin to give final
concentration of 200 nM ATIII in each well. The mixture was incubated at 37°C for 10 min
followed by addition of 5 μl of 5 mM Spectrozyme TH. The residual enzyme activity was
determined from the initial rate of increase in absorbance at 405 nm. The apparent IC50 was
calculated using logistic equation 4 along with other inhibition parameters such as YM, Y0 and
HS.

Inhibition of Activation of Protein C by Thrombin-Thrombomodulin Complex in the presence of
SbO4L
The protocol for measuring the activation of protein C by thrombin–thrombomodulin (TH-TM)
complex was adapted to a 96-well format from the literature.193 Briefly, in 70 μl of 50 mM TrisHCl buffer, pH 7.4, containing 100 mM NaCl, and 1 mM CaCl2, 5 μl of SbO4L was added at
concentrations ranging from 2.3 ng/ml to 2.3 mg/ml at 37°C, followed by addition of 5 μl of
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thrombin (240 nM) and 5 μl of TM (400 nM). The mixture was incubated for 10 min and 5 μl of
protein C (10 μM) added and incubated at 37°C for another 10 min. After this period, further
generation of activated protein C (APC) was quenched by the addition of 5 μl mixture of 10 mM
EDTA and 16 μM argatroban (≈20x Ki). The APC generated was quantified from the initial rate
of chromogenic substrate hydrolysis of 400 μM S-2366. The percent activation of protein C was
calculated from initial rate in the presence and absence of SbO4L and the apparent IC50 was
calculated in a similar manner using equation 4.

Variation of SbO4L Inhibition on Various Types of Thrombins
In order to establish inter-species variability in the inhibitory potential of SbO4L and efficacy
against thrombin degradation enzymes, chromogenic substrate hydrolysis assays were performed
on human, mouse, bovine and gamma thrombin using a 96-well microplate format. Briefly, 5μL
of either water or SbO4L at concentrations ranging from 2.3 ng/ml to 2.3 mg/ml was diluted with
185μL of 20mM Tris-HCl buffer, pH 7.4, containing 100mM NaCl, 2.5mM CaCl2, and 0.1%
PEG 8000 in a 96-well polystyrene microplate at 37°C. To this was added 5μL of thrombin to
give 6nM of the different thrombin in separate series. The solution was incubated for 10 minutes,
following which 5μL of 5mM chromogenic substrate Spectrozyme TH was added. The residual
activity of thrombin was determined by monitoring the initial rate of product formation at 405
nm wavelength. The percent residual activity and the IC50 was determined using logistic equation
4.
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Fibrinogen Assay
To test if SbO4L was active against physiologically relevant substrate fibrinogen, the following
microplate assay was performed. Briefly, in 35 μL of buffer (20mM TrisHCl, 100mM NaCl,
2.5mM CaCl2 0.1% PEG8000, pH 7.4), 10 μL of thrombin (300nM) was added along with either
5μL of water as control or SbO4L at concentrations ranging from 2.3μg/ml to 5.6 mg/ml. The
mixture was incubated for 10 minutes at 37°C, after which 10 μL of this reaction was added to
140 μL of 250 nM of fibrinogen. The formation of fibrin mesh was observed as absorbance at
600 nm for the first 100 seconds after initiation of the reaction. The slope was used to get the rate
of enzyme activity towards fibrinogen cleaving activity. The percent residual activity and IC 50
were calculated in a manner similar to that done for the peptide chromogenic substrate reactions
using equation 4.

Michaelis Menten Kinetics
To assess the nature of the inhibition of thrombin by SbO4L Michaelis-Menten kinetics
experiments were performed in the presence of various concentrations of the inhibitor using
previously reported protocols.183,188,189 The initial rate of Spectrozyme TH hydrolysis by 3 nM
thrombin was monitored from the linear increase in absorbance at 405 nm corresponding to less
than 10% consumption of the substrate. The initial rate was measured as a function of substrate
concentrations (0.6 to 20 µM) in the presence of a fixed concentration of SbO4L (0–2.3 μg/ml)
in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2 and 0.1 %
PEG8000 at 25°C in a cuvette. Standard Michaelis-Menten equation was used to calculate KM
and VMAX (Eq. 5).
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(Eq. 5)

Competition with Heparin, Hirugen Peptide and recombinant GPIba
SbO4L-dependent thrombin inhibition studies in the presence of competitors were performed as
described earlier.183 SbO4L (0–23 μg/ml) was incubated with either HirP (0 – 86 nM) or porcine
UFH (0–100 μM) and thrombin (5 nM) in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM
NaCl, 2.5 mM CaCl2 and 0.1 % PEG 8000 at 25°C in PEG20000-coated polystyrene cuvettes for
10 minutes. For competition with GPIbα, SbO4L (0-1mg/ml) was incubated with GPIbα (0458nM) and thrombin (6 nM) in 10mM HEPES buffer with 10mM Tris-HCl, pH 7.8 containing
100mM NaCl and 0.1% PEG 8000 in 96-well plate for 10 minutes. Following incubation,
Spectrozyme TH (100 μM) was added and the initial rate of 405 nm absorbance change was
measured. The dose-dependence of the fractional residual protease activity at each concentration
of the competitor was fitted by equation 1 to calculate the IC50,app of inhibition. The molecular
weight of porcine UFH was assumed to be 15,000, while its affinity was measured earlier in the
laboratory (15.6±3.1 μM).183
To quantify the degree of competition of SbO4L with its competitors, the Dixon-Webb
relationship was used to calculate the apparent IC50,app of the inhibitor in the presence of a
competitor with known affinity (Kcompetitor).183,190 The equation is given as:

(Eq. 6)
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Mutagenesis Studies
To localize the important residues for binding of SbO4L in the exosite 2 of thrombin, SbO4L
inhibition of various thrombin mutants was performed. The IC50 of SbO4L against recombinant
mutants of thrombin was measured using the chromogenic hydrolysis assay in a 96-well format.
In general, SbO4L (0-2 mg/ml) was incubated with individual mutants of thrombin (6 nM) in a
20 mM Tris-HCl buffer containing 100 mM NaCl, 2.5 mM CaCl2, 0.1% PEG 8000 at a pH 7.4
for 10 minutes. Following this, substrate Spectrozyme TH (100 μM) was added to the reaction
and the intial rate of increase in absorbance at 405nm was measured. The rate of initial
hydrolysis was used to calculate residual thrombin activity, which was used to calculate the IC50
from equation 4.

Probing Allosteric Change in Active Site using Quenching
Accessibility of the active site in the presence of SbO4L can be probed using a labeled enzyme
and a collisional quencher.194 199 μL of buffer containing 20 mM Tris HCl, 100mM NaCl, 2.5
mM CaCl2, 0.1% PEG 8000 at pH 7.4 was taken in a quartz cuvette. To this was added 1 μL of
fFPR-Thrombin such that the final concentration of the enzyme was 170 nM. 3 μL of either
water or 3mg/mL SbO4L was added. The fluorescence intensity was monitored using a QM4
fluorometer (Photon Technology International, Birmingham, NJ) which was thermostated with a
water bath at 25°C using excitation and emission wavelengths of 490 nm and 522 nm
respectively, with slit-widths of 4nm each. The solutions were titrated with increasing
concentrations of the quencher acrylamide (stock of 10 M with 1 μL additions) and the
fluorescence intensity monitored after each addition.
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The ratio of the fluorescence without the quencher (F0) to the fluorescence in the presence of
various concentrations of the quencher (F) can be plotted against the quencher concentration (Q)
to yield a linear relationship which can fit the Stern-Volmer relationship194:
(Eq. 7)

Where kq is the bimolecular quenching constant,

is the fluorophore lifetime in the absence of

the quencher and Q is the concentration of the quencher. KSV in this case is the Stern-Volmer
constant and is equal to kq .

Quantitating Number of Ionic Interactions Involved by Salt Dependence Studies on Affinity
To study the salt dependence of SbO4L interaction with thrombin, a fluorescence binding study
was carried out using buffers having different concentrations of sodium chloride. Briefly, in 199
μL of buffer containing 20 mM Tris HCl, 2.5 mM CaCl2, 0.1% PEG 8000 at pH 7.4 containing
various concentrations of NaCl (100-200 mM), 1μL of fFPR-Thrombin was added, to give a final
concentration of 170 nM in the quartz cuvette. The experiments were performed using a QM4
fluorometer (Photon Technology International, Birmingham, NJ) which was thermostated with a
water bath at 25°C. The mixture was then titrated with SbO4L and the decrease in fluorescence
was monitored using excitation and emission wavelengths of 490 nm and 522 nm respectively,
with slit widths of 4nm each. The decrease in fluorescence signal was fit to a quadratic equation
to obtain the dissociation constant at various concentrations of salt:
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Where, ΔF represents the change in fluorescence of fFPR-Thrombin at each addition of SbO4L
from the initial fluorescence F0. ΔFMAX represents the maximal change in fluorescence observed
when the enzyme is saturated with the inhibitor. [E] 0 is the enzyme concentration which is a
constant for the experiment, while [SbO4L] 0 is the concentration of the inhibitor during the
titration. KD is the dissociation constant of the complex.
The dissociation constant (KD) so obtained was further expressed as a linear function of the salt
concentration according to the expression:
-log KD = A0 + Γsalt log [salt]

(Eq. 9)

The slope of the line yields Γsalt which represents a thermodynamic measure of the effect of salt
concentration on binding equilibria, which can be compared with other exosite binding ligands.

Reversal of SbO4L Mediated Thrombin Inhibition by Protamine
To test whether SbO4L inhibition of thrombin can be reversed by protamine, a solution of
SbO4L (575 ng/ml) along with thrombin (6nM) in a 20 mM Tris-HCl buffer, pH 7.4, containing
100 mM NaCl, 2.5 mM CaCl2 and 0.1% PEG8000 at 37°C was gradually titrated with protamine
(4.9 ng/ml to 14.8 mg/ml) such that the final volume was 195 μl. The solution was incubated for
10 minutes followed by addition of 5 μl of Spectrozyme TH (5 mM) and the increase in
absorbance at 405 nm observed. In the absence of protamine, SbO4L gave ~50% inhibition of
thrombin at 37°C. Protamine alone did not affect the activity of thrombin as assessed by
appropriate controls. The sigmoidal gain in thrombin activity could be fitted by the equation 4 to
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obtain the effective concentration of protamine necessary to recover thrombin from SbO4L
inhibition by 50%.

3.3 Results
Synthesis of SbO4L
The synthesis of SbO4L was accomplished using a 7-step synthetic protocol starting from
commercially available vanillin (1). The key to the formation of the β-O4 lignin 7 is in the
formation of reactive monomer 5. The synthesis of monomer 5 was previously reported,195
however, the strategy was not reproducible and often yielded lower yields than reported. This
was largely due to the fact that the deprotection of the benzyl group involved palladiumcatalyzed hydrogenation which also resulted in the reduction of the α-keto to an alcohol. This
resulted in lower overall yield. Additionally, the β-alcohol ester side product was rendered less
reactive for bromination at the α-position, and therefore could not be used further. As a result we
developed a novel strategy for synthesis using TBDMS protection (Figure 16).
TBDMS protection of vanillin afforded compound 2 in almost quantitative yields at a
large scale (>20 g). Synthesis of β-keto ester from aldehydes was reported earlier for vanillin
derivatives with benzyl protecting group as a two step process using reactive reagents such as
diethyl aluminium.195 Alternatively, the paper also proposed the synthesis of beta-ketoester in a
single step from acetovanillone using sodium hydride and ethyl carbonate. Such reactions could
not work with TBDMS protection. Hence we adapted a milder method utilizing niobium (V)
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chloride and ethyldiazoacetate.196 The reaction had to be optimized for use with TBDMS
protecting group with a reduction in temperature while addition of ethyldiazoacetate to prevent
deprotection and other side reactions due to the heat generated from the reaction. This method
produced the beta-ketoester 3 on a sufficiently large scale (>7 g) with good yield.
Deprotection of the TBDMS group was then performed using potassium fluoride with
catalytic quantities of acetic acid to produce 4 in good yields and scale (> 3 g). Bromination was
previously reported to have been performed using elemental bromine.195 Use of elemental
bromine requires special care as it is highly toxic. Furthermore, handling of the reagent and
weighing can be difficult. As a result, one can often get higher orders of bromination or
incomplete reactions. We therefore explored an alternative to synthesize the α-bromo. Selective
mono-bromination at the α-position of the β-keto ester was performed with the use of
bromodimethyl sulfonium bromide (BDMS) reagent.197 BDMS reagent can be freshly prepared
to yield a yellow powder which can be easily handled. This reaction was surprisingly very clean
and the product 5 formed required no purification apart from simple aqueous work up. Since αbromo-β-keto esters are reactive and susceptible to degradation, fresh monomer 5 was produced
every time prior to polymerization.
Polymerization of 5 using K2CO3 to form 6 and its subsequent reduction using NaBH4 to
form the β-O4 lignin 7 was performed using methods previously described.198,199 While the
polymerization step gave good yields, reduction and subsequent purification to form 7 showed
some loss of compound due to separation of lower molecular weight species from the polymer
by precipitation. The NMR of the products obtained for these two steps matched well with the
literature records.198,199 A final step of sulfation was adapted from the sulfation methodologies
used to create the chemoenzymatically synthesized lignins.182,183 The β-O4 lignin polymer was
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reacted with sulfating agent following which the counterion on the sulfated polymer was
exchanged using sodium acetate resulting in a highly water soluble polymer which could be
purified by precipitation (with ethanol) and dialysis/ultrafiltration to afford purified SbO4L.
NMR characterization of SbO4L was challenging due to the fact that it was a heterogeneous
mixture. Further characterization of SbO4L was carried out using size exclusion chromatography
and reversed-phase ion-pairing chromatography, to establish reproducibility in the synthesis, as
well as to determine length of the polymeric species.
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Figure 16. Synthetic scheme for production of SbO4L
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SbO4L is a Sulfated Polymeric Species which can be Reproducibly Synthesized
Characterizing sulfated polymers is extremely challenging. 1H and

13

C NMR signals are

relatively lower due to the lower relative abundance of these atoms within sulfated molecules as
well as heterogeneity of molecules. Furthermore, SbO4L represents a polymeric mixture thus
preventing the presentation of distinct peaks in these techniques. We characterized the final
product of the synthesis of SbO4L using a combination of techniques such as size exclusion
chromatography (SEC) HPLC, elemental analysis and reversed-phase ion pairing (RPIP) UPLCMS.
The SEC chromatography is often used for the characterization of hydrophilic polymers.
It gives an idea of the total size of the polymeric species. SbO4L elutes at 9.62 minutes which
correlates to an elution volume of 6.74 ml in the method adopted (Figure 17A). A plot of log
MW vs elution volume of known polystyrene sulfonate standards in the SEC method yields a
straight line (Figure 17B) which can be used to extrapolate the molecular weight parameters of
SbO4L. The aqueous SEC-HPLC profile of SbO4L indicated the number (MN), weight (MW) and
peak (MP) average molecular weights of 9200, 12300, and 9100, respectively, which implied that
on an average SbO4L chain is ~23 residues long. In comparison, an average UFH chain is 50
residues long. The SEC chromatograms also indicated that there were no peaks less than
molecular weight of 1000 Da indicating that the purity of the polymeric species was greater than
98%. The polydispersity (P), of SbO4L was found to be 1.336, which is similar to that of UFH
used in the clinic.200 The sulfation density calculated on the basis of the difference in M W
between SbO4L and its unsulfated precursor was ~2 sulfate groups per monomer, which
compares favorably with that of UFH and LMW heparins (~1.65 negative charges per
monomer). However, calculation of sulfation using SEC can be exaggerated due to the
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association of water molecules along with the sulfates. In combination, the uniform β-O4 linkage
and the high sulfation density of SbO4L suggests a fairly uniform repeating structure in
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Figure 17. Characterizing molecular size of SbO4L. (A) SEC chromatograms for PSS standards,
monomer ferrulic acid and SbO4L. (B) Plot of log MW vs elution volume of PSS standards yields
a straight line which can be used to calculate the MP of SbO4L.

Elemental analysis gives useful information about the total elemental composition of the
molecule, and can be useful in determining purity as well as ratio of functional groups (such as
sulfates) within a molecule. Elemental analaysis indicates that the sulfation level is closer to 1.25
sulfate groups per monomer which is less than that of heparin and suggests that SbO4L may
contain associated waters.
Further purity and reproducibility of synthesis was confirmed using reversed-phase ion pairing
UPLC-MS and in vitro thrombin inhibition test for three different batches of synthesized
polymer. The three batches of SbO4L demonstrated similar UPLC chromatograms in a
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fingerprint like manner (Figure 18A), while showing identical IC50 for thrombin inhibition (0.20
± 0.04 μg/ml) (Figure 18B).
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Figure 18. Comparison of three different batches of SbO4L using RPIP-UPLC-MS and
Thrombin Inhibition. (A) Shows the total ion chromatogram (TIC) for the RPIP-UPLC-MS
performed on three different batches of SbO4L. (B) Thrombin inhibition by three different
batches of SbO4L shows identical decrease in residual activity of thrombin with an IC50 of
0.20μg/ml.

SbO4L is a Selective and Potent Inhibitor of Thrombin and Plasmin among the Coagulation
Enzymes.
To assess the selectivity of inhibition of SbO4L toward the different coagulation
proteases, the inhibition of all relevant coagulation enzymes was studied using a chromogenic
substrate assay in the presence of varying levels of SbO4L, using methods which have been
adapted previously.148,151 The decrease in residual protease activity as SbO4L was varied over
105-fold was fitted using the dose-response equation 4 to calculate the IC50, hill slope (HS),
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maximal (YM) and minimal activity (Y0) parameters (Figure 19, Table 2). SbO4L inhibited
human α-thrombin with an IC50 of 0.17 μg/ml (~18 nM), while fXa and fXIa were inhibited at
90–500 μg/ml SbO4L (~10–55 μM). In comparison, parent LMW lignins inhibited fXa with IC50
of 34-120 nM and fXIa with an IC50 of 22-176 nM (Table 1).186 Finally, inhibition of FIXa was
not noticeable at concentrations as high as 81 μg/ml (8.7 μM), while fVIIa–recombinant tissue
factor (rTF) complex was inhibited 50% at 9.4 μg/ml (1 μM) SbO4L. The only coagulation
protein that displayed inhibition close to thrombin was plasmin, with an IC50 of 0.38 μg/ml (~40
nM). However, this is not surprising as the parent lignins were also found to inhibit plasmin in a
potent, allosteric manner and there seems to be structural resemblance between the heparin
binding sites of these proteins.185 The results indicated that SbO4L inhibited human thrombin
~20 – 2940-fold better than the closely related coagulation factors. This is a significant
improvement in selectivity compared to parent chemoenzymatically synthesized lignins (Table
1). Also, most sulfated GAGs including UFH and fondaparinux do not inhibit these enzymes
directly at concentrations as high as 100 μg/ml.183
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Figure 19. Direct inhibition of serine proteases of the coagulation cascade by SbO4L. The
inhibition of factors IIa (thrombin, fIIa), Xa, XIa, IXa, VIIa, VIIa-tissue factor (TF) complex and
plasmin by SbO4L was monitored using chromogenic substrate hydrolysis assay. The % residual
activity of the enzymes was plotted against the log of the concentration to obtain a dose response
curve which can be fitted to equation 4 to give the IC50, YM, Y0 and HS parameters of inhibition.
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Table 2. Parameters for sulfated β-O4 lignin (SbO4L) inhibition of coagulation proteases. a
Protease

log [IC50 (g/ml)]

IC50 (μg/ml)

YM

Y0

HS

Thrombin

-6.8  0.1 b

0.17  0.01

99  1

29  1

1.6  0.1

Factor Xa

-3.3  0.6

500  300

100  4

~1

0.5  0.2

-

-

Factor IXa

NI

Factor XIa

c

d

NI

-

-4.1  0.1

89  9

98  3

41  2

1.0  0.2

Factor VIIa

-6.3  0.1

0.54  0.05

103  3

31  3

1.1  0.1

Factor VIIa – TF

~ -5.0 e

>11 e

100  2

~38 e

~0.5 e

-6.4  0.1

0.38  0.04

103  1

31  2

1.1  0.1

-6.7  0.1 b

0.20  0.01

64  1

61

1.9  0.4

-5.4  0.1

4.20  0.08

98  2

35

0.96 

Plasmin
Thrombin w/ AT

f

Thrombin/rTM – PC
g

0.14
The IC50, HS, YM, YO values were obtained following non-linear regression analysis of direct
inhibition of the protease (see ‘Experimental Methods’ for details). bErrors represent  1 S. D.
c
No inhibition was observed up to concentrations as high as 81 μg/ml. dNot applicable.
e
Estimated values. fIn the presence of 200 nM AT. gInhibition of activation of protein C by
thrombin – thrombomodulin complex.
a

SbO4L does not Inhibit Other Heparin Binding Serine Proteases
To assess the selectivity against other heparin-binding serine proteases, we screened
cathepsin G, human leukocyte elastase, kallikrein, porcine pancreatic elastase, activated protein
C, plasmin, chymotrypsin, and trypsin, as studied earlier for sulfated LMW lignins.186 Except for
plasmin and factor VIIa, the activity of each protease remained relatively unaffected in the
presence of 81 μg/ml (8.7 μM) SbO4L (Figure 20) suggesting more than 475-fold selectivity.
Factor VIIa inhibition by SbO4L does not exist in the physiologically relevant complex with
tissue factor (TF), suggesting that SbO4L would be a selective inhibitor of plasmin and thrombin
in the blood. Thus, SbO4L selectively inhibits human thrombin and plasmin among several
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structurally similar and relevant trypsin-like proteases. This is a significant improvement in
selectivity compared to parent LMW lignins which were also found to be potent inhibitors of
cathepsin G (90-230 nM), HLE (9-17nM), and plasmin (240-1290nM) (Table 1).

% Residual
Protease Activity

125
100
75
50

25
0

Figure 20. SbO4L inhibition of other heparin-binding serine proteases including cathepsin G,
human leukocyte elastase (HLE), porcine pancreatic elastase (PPE), activated protein C (APC),
plasmin, chymotrypsin and trypsin at a fixed 81 μg/ml (8.7 μM) (~475-fold excess over the IC50
of thrombin inhibition).
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Antithrombin III does not Potentiate SbO4L Mediated Thrombin Inhibition
Polymeric heparin is a powerful antagonist of thrombin because of its ability to bind
plasma antithrombin and bridge with thrombin.201 In contrast, sulfated LMW lignins were found
to bind the serpin with reasonable affinity, yet lose direct inhibition potential.191 To assess the
influence of antithrombin on SbO4L activity, direct inhibition of thrombin was studied in the
presence of 200 nM serpin under otherwise identical conditions. A decrease in thrombin activity
with increasing SbO4L levels was observed, which was identical to that measured in the absence
of the serpin, except for the differences in maximal (YM) and minimal (Y0) residual thrombin
activities (Figure 21, Table 2). The YM and Y0 values decreased by 35% and 23%, respectively,
due to the reaction of thrombin with antithrombin. However these changes did not affect SbO4L
inhibition of thrombin (IC50 = 0.2 and 0.17 μg/ml with and without antithrombin, respectively
(Table 2)). The result implies that antithrombin does not retard or stimulate SbO4L’s inhibitory
activity. This is a significant point of difference from the parent sulfated LMW lignins, for which
the serpin-mediated pathway was found to be a competing side reaction.191 The results highlight
an interesting structural aspect that a specific scaffold, i.e., the β-O4-linked scaffold, of the many
possible in sulfated LMW lignins does not appear to bind the serpin with high affinity, which
improves mechanistic selectivity.
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Figure 21. Effect of antithrombin III on SbO4L inhibition of thrombin. Inhibition of thrombin in
the presence of antithrombin III (w/ AT) with SbO4L (●) was compared to SbO4L alone (○). A
decrease in YM and Y0 was observed due to direct inhibition of thrombin with antithrombin III.
However, no change in IC50 was observed.

SbO4L Inhibits Thrombomodulin-Bound Thrombin Less Potently
Thrombin’s procoagulant activity is highly regulated by cell surface thrombomodulin
(TM), which transforms it into an anticoagulant protease with specificity for protein C.15,202 To
assess whether TM binding to thrombin alters the activity of SbO4L, we studied the efficacy of
protein C activation. The level of proteolytically active protein C formed by thrombin–TM
complex can be measured spectrometrically through hydrolysis of S-2366193 following
suppression of thrombin’s native proteolytic activity using argatroban (~20  Ki)203 as its specific
inhibitor. Measurement of APC levels in the presence of varying SbO4L levels led to a sigmoidal
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profile on a semi-log plot (Figure 22) suggesting that SbO4L inhibited the protein C activation
potential of thrombin–TM complex. The IC50 was measured to be 4.2 μg/ml (Table 2), which
was ~20-fold higher than that measured for SbO4L inhibiting the procoagulant activity of
thrombin alone. The efficacy of inhibition of protein C activation was found to be nearly 100%
(Table 2), which is higher than that for thrombin alone (~70%, Table 2). Although the higher
efficacy may appear to imply that the procoagulation potential of SbO4L is higher than the
anticoagulant potential, protein C activation is inhibited at 20-times the concentration of
thrombin inhibition. Thus, the results indicate that SbO4L is a selective inhibitor of the
procoagulant form of thrombin compared to the anticoagulant form of it.
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Figure 22. SbO4L inhibition of thrombin-thrombomodulin complex. Inhibition of protein C
activation potential of thrombomodulin-bound thrombin by SbO4L (○) in comparison to
thrombin proteolytic activity (□). A shift in the dose response curve to the right by almost 1-log
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unit shows a change in the potency of almost 20-fold. This is a clear sign that SbO4L can inhibit
free thrombin with greater potency than thrombomodulin-bound thrombin.

SbO4L Inhibits Different Types of Thrombin in Equivalent Manner
Small structural differences exist between thrombin structures between different species
and the degradation products of thrombin. Therefore there is a need to establish SbO4L potency
against thrombin from different species and γ-thrombin. In order to assess variation of inhibition
of SbO4L versus different types of thrombin, we screened SbO4L against mouse (murine), cow
(bovine) thrombin and γ-thrombin (Figure 23). It was found that SbO4L shows little or no interspecies variation of thrombin inhibition with an IC50 of 0.17 ± 0.03 μg/ml. However, SbO4L
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does show a slight decrease in potency against γ-thrombin with an IC50 of 0.34 ± 0. 03 μg/ml.
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Figure 23. Inhibition of different types of thrombin by SbO4L. A comparison of the activity of
SbO4L against human α-thrombin (□), murine thrombin (Δ), bovine thrombin (○) and human γ80

thrombin (◊) was performed. It was observed that SbO4L inhibited the different species of
thrombin with equal potency (IC50 = 0.17 μg/ml), while inhibiting γ-thrombin with 2-fold less
potent IC50 of 0.34 μg/ml.
SbO4L Shows Similar Potency Against Thrombin for Fibrinogen Substrate
Since all ex vivo and in vivo experiments will be close to physiological conditions, we
thought it would be useful to assess SbO4L inhibition of thrombin using physiologically relevant
fibrinogen as the substrate. The assay monitors the change in absorbance due to formation of
fibrin mesh in the presence of SbO4L which is compared to a reaction without the inhibitor to
obtain the residual activity. A plot of the residual activity as a function of the concentration gives
a curve similar to those observed with chromogenic substrates and can be fitted to equation 4
(Figure 24) . The IC50 for SbO4L with fibrinogen at 0.19 ± 0.09μg/ml thus obtained was similar
to the IC50 with chromogenic substrate at 0.17 ± 0.01μg/ml.
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Figure 24. Shows the inhibition of thrombin mediated conversion of fibrinogen to fibrin by
SbO4L.
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SbO4L is a Non-Competitive Inhibitor of Thrombin
To understand the basis of thrombin inhibition, we measured the kinetics of Spectrozyme
TH hydrolysis at pH 7.4 in the presence of SbO4L. Plots of the initial rates versus substrate
concentration were hyperbolic, as expected (Figure 25). As the concentration of SbO4L was
increased from 11.5 ng/ml to 2.3 μg/ml, maximal velocity of hydrolysis, VMAX, decreased in a
dose dependant manner (Table 3). Fitting the data using the standard Michaelis-Menten equation
gave an essentially invariant KM,app of 1.5 μM (Table 3). This suggests that SbO4L does not
affect small molecule chromogenic substrate binding to the active site of thrombin. The VMAX
decreased from 27.5 to 7.4 mAbsU/min (Figure 25) corresponding to a decrease of more than
70%. Thus, SbO4L appears to not sterically hinder the interaction of thrombin substrate, but
brings about changes in the active site that reduce the catalytic rate. This implies that SbO4L is a

Initial Rate of
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non-competitive, allosteric inhibitor of human thrombin.
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Figure 25. Michaelis-Menten kinetics of Spectrozyme TH hydrolysis by thrombin in the presence
of SbO4L. The initial rate of hydrolysis at various substrate concentrations was measured in a
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pH 7.4 buffer as described in ‘Experimental Procedures’. The concentrations of SbO4L were 0
(), 0.012 (), 0.115 (), 0.230 (∆) and 2.3 μg/ml (). Solid lines represent non-linear fits to the
data using the standard Michaelis-Menten equation.
Table 3. The Michaelis-Menten Kinetic Parameters of SbO4L Inhibition of Thrombin
[SbO4L]
(μg/ml)
0

KM
(µM)
1.6 ± 0.2

VMAX
(mAbsU/min)
27.5 ± 0.7

0.0115

1.7 ± 0.3

20.0 ± 0.1

0.115

1.3 ± 0.1

14.8 ± 0.1

0.230

1.5 ± 0.3

11.7 ± 0.5

2.3

1.4 ± 0.1

7.4 ± 0.1

SbO4L does not Compete with Exosite 1 Ligand Hirugen Peptide, but Competes with Exosite 2
Ligands Heparin and GPIbα
To assess whether SbO4L engages one or both exosites of thrombin, competitive
inhibition studies were performed using prototypical ligands, hirugen (exosite 1) and heparin
(exosite 2). HirP, a hirudin-based dodecapeptide that binds avidly to exosite 1 (KD = 28 nM),204
did not affect the apparent IC50 of thrombin inhibition by SbO4L at concentrations nearly 3.1
times higher than the affinity (Figure 26, Table 4). This implies that the SbO4L does not engage
exosite 1 of thrombin. When the thrombin inhibition was studied in the presence of both SbO4L
and UFH (KD = 15.6 μM, MW = 15,000)183, the IC50 increased from 0.2 to 1.25 μg/ml (Figure
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27A, Table 4), which paralleled that predicted by the Dixon-Webb relationship for ideal
competitive behavior (Figure 27B). This implied that SbO4L competes with UFH for binding to
human thrombin, which suggests interaction with residues in or near exosite 2. To further
understand SbO4L allostery, we decided to utilize recombinant GPIbα (Ki = 100 nM)80, which is
known to bind exosite 2 of thrombin.52 Although GPIbα inhibits thrombin-mediated fibrinogen
to fibrin conversion, it does not affect thrombin’s hydrolysis of small peptides.80 As the
concentration of GPIbα increases from 0 to 458 nM, the IC50 of SbO4L inhibition of thrombin
increased from 0.17 to 1.15 μg/ml, which paralleled the predicted values assuming ideal
competition (Figure 28A and 28B). Thus, SbO4L competes with GPIbα for binding to thrombin.
This implies that exosite 2 residues that are important for both UFH and GPIbα are likely to be
important for binding to SbO4L.
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Figure 26. Effect of exosite-1 binding competitor hirudin-based peptide (HirP) on the inhibition
of thrombin by SbO4L. The inhibition of human α-thrombin was studied through Spectrozyme
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TH hydrolysis assay at pH 7.4 in the presence of fixed concentrations of the competitor HirP.
Solid lines represent dose-response curves formed by fitting the data points to equation 4.
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Figure 27. Effect of exosite-2 binding competitor unfractionated heparin (UFH) on the
inhibition of thrombin by SbO4L. (A) The inhibition of human α-thrombin was studied through
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Spectrozyme TH hydrolysis assay at pH 7.4 in the presence of fixed concentrations of the
competitor porcine UFH. Solid lines represent dose-response curves formed by fitting the data
points to equation 4 to yield the IC50 at various concentrations of the competitor. (B) Analysis of
ideality of competition between SbO4L and porcine UFH. A comparison between the observed
IC50 (in black) and those calculated using the Dixon-Webb relationship (Eq. 6) (in grey) at
different concentrations of UFH (0-100 μM) demonstrates that porcine UFH competes
effectively against SbO4L thereby causing an increase in IC50 which is comparable to the
predicted IC50 for ideal competition.
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Figure 28. Effect of exosite-2 binding ligand GPIbα on the inhibition of thrombin by SbO4L. (A)
The inhibition of human α-thrombin was studied through Spectrozyme TH hydrolysis assay at pH
7.4 in the presence of fixed concentrations of the competitor GPIbα. Solid lines represent doseresponse curves formed by fitting the data points to equation 4 to yield the IC50 at various
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concentrations of the competitor. (B) Analysis of ideality of competition between SbO4L and
GPIbα. A comparison between the observed IC50 (in black) and those calculated using the
Dixon-Webb relationship (Eq. 6) (in grey) at different concentrations of GPIbα (0, 229 and 458
nM) demonstrates that GPIbα competes effectively against SbO4L thereby causing an increase
in IC50 which is comparable to the predicted IC50 for ideal competition.

Table 4. Inhibition parameters of human α-thrombin by SbO4L in the presence of exosite 1
(HirP) and exosite 2 (UFH and GPIbα) ligands.
IC50

YM

Y0

HS

[HirP] nM

(μg/ml)a

0

0.15  0.01b

102  14

24  1

1.2  0.1

8.6

0.17  0.02

103  2

23  1

1.2  0.1

86

0.14  0.02

102  3

17  2

1.2  0.2

0.2

0.22  0.01

99  1

26  1

1.6  0.1

2.0

0.34  0.02

98  1

26  1

1.8  0.1

20

0.66  0.05

96  1

24  1

1.6  0.2

100

1.25  0.14

100  1

28  2

0.9  0.1

0

0.23 ± 0.01

101 ± 2

18 ± 1

1.5 ± 0.1

229

0.69 ± 0.05

99 ± 1

22 ± 1

1.5 ± 0.1

458

1.15 ± 0.05

101 ± 2

28 ± 1

1.6 ± 0.1

[UFH] μM

[GPIbα] nM

a

The IC50, HS, YM, YO values were obtained following non-linear regression analysis of direct
inhibition of human α-thrombin. bErrors represent  1 S. E.
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SbO4L Mediates Thrombin Inhibition via Binding to Arg233, Lys235 and Lys236 residues on
Exosite 2.
To pinpoint the exosite 2 residues that interact with SbO4L, we studied 11 recombinant
thrombins containing substitution of basic residues with alanine. These single- or multi-site
thrombin mutants have been shown earlier to possess fully functional catalytic machinery.190,205
Alanine replacement at either Arg126, Arg165, Lys169, Arg173, Arg175, or Lys240 showed
minimal change (0.9 – 2.1-fold) in SbO4L inhibitory potential as compared to their wild-type
recombinant reference (Figure 29A, Table 5). Likewise, a triple mutant containing
Arg93,101,107Ala did not affect the IC50. However, single-site alanine substitution at Arg233,
Lys235, and Lys236 positions was found to have 8 – 9-fold increase in IC50 as compared that for
the wild-type thrombin indicating that each of these residues are important for SbO4L-mediated
inhibition of thrombin (Figure 29A and 29B, Table 5). Interestingly, these residues are also
known to be crucial for interaction with heparin206 and GPIbα52,116,117.
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Table 5. Inhibition parameters of SbO4L for different thrombin exosite 2 mutants in
comparison to wild type recombinant protein.
Thrombin
Enzyme

IC50
(μg/ml)a

YM

Y0

HS

WT

0.34  0.03b

102  3

14  1

1.5  0.2

Triple Mutant

0.52  0.07

101  3

32  2

1.4  0.3

R126A

0.67  0.04

101  1

18  1

1.3  0.1

R165A

0.41  0.06

100  3

33  2

1.3  0.2

K169A

0.55  0.02

101  1

15  1

1.6  0.1

R173A

0.32  0.04

103  2

35  1

1.2  0.1

R175A

0.66  0.03

102  1

25  1

1.2  0.1

R233A

3.2  0.1

99  1

16  1

1.4  0.1

K235A

2.8  0.2

100  1

17  1

1.4  0.1

K236A

2.8  0.2

97  1

16  1

1.3  0.1

K240A

0.73  0.02

99  1

22  1

1.5  0.1

a

The IC50, HS, YM, YO values were obtained following non-linear regression analysis of direct
inhibition of human α-thrombin. bErrors represent  1 S. E.
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Figure 29. Effect of SbO4L on Thrombin Mutants (A) Shows a comparison of SbO4L inhibition
of mutant vs wild type (WT) for the different thrombin mutants which included a triple mutant
(Tpl Mut) R93,97,101A, R126A, R165A, K169A, R173A, R175A, R233A, K235A, K236A and
K240A. (B) Shows the representative dose response curves for SbO4L inhibition for recombinant
thrombin mutants R233A, K235A and K236A in comparison to wild type (WT) thrombin.
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SbO4L Causes Allosteric Change in Active Site that restricts Quenching by Acrylamide
To check accessibility of the active site upon SbO4L binding, quenching studies were
carried out on fFPR-Thrombin using the collisional quencher- acrylamide. Collisional quenching
occurs when the fluorophore comes in contact with the quenching agent in the excited state. If
the binding of SbO4L causes a dramatic conformation change within the active site, the active
site fluorescein of fFPR-Thrombin would be less accessible to quenching by the collisional
quencher acrylamide. We observed that SbO4L bound fFPR-Thrombin was more resistant to
collisional quenching compared to fFPR-Thrombin alone (Figure 30A). Upon treating the data
thus obtained in the Stern-Volmer relationship we noticed that the Stern-Volmer relationship
fitted well with a linear relationship (Figure 30B), indicating one type of fluorophore present
both with and without inhibitor. The quenching constant (KSV) obtained from the slope, was
almost 80% lower in the presence of SbO4L, suggesting that the conformational change induced
restricts the accessibility of the quenching agent by a great extent. This is a clear indication of a
dramatic change in the active site conformation due to SbO4L binding to thrombin.
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Figure 30. Active site fluorescence quenching in presence of SbO4L (A) The fluorescence
intensity of fFPR-Thrombin was monitored with and without SbO4L at various concentrations of
collisional quencher acrylamide. It was observed that the enzyme active site fluorescein was
more susceptible to quenching in the absence of SbO4L compared to in its presence. Further,
there was a recovery of fluorescence (shown in grey arrow) when SbO4L was added to the
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enzyme alone after addition of final concentration of acrylamide. (B) Stern-Volmer plots further
showed that there was approximately 80% reduction in the quenching constant in the presence of
SbO4L suggesting that the fluorophore was less accessible for quenching.

SbO4L binds Exosite 2 with Approximately Five Ionic Interactions
Exosite 2 binding ligands are in general highly ionic in nature. To learn about the ionic
contributions of SbO4L while binding to thrombin we performed salt dependence binding
affinity studies. The affinity was measured by monitoring the change in fluorescence of activesite labeled fFPR-Thrombin in titrations with SbO4L. It was observed that as the concentration
of salt increased, the binding affinity of SbO4L for thrombin decreased (Figure 31A, Table 6). A
plot of the log of the dissociation constant as a function of log of the salt concentration yielded a
straight line (Figure 31B) with a R2 of 0.98, whose slope gave the Γsalt value of -5.0 (Equation
9). This is comparable to other exosite 2 binding ligands such as reported values of GPIbα and
Heparin (Table 7). Γsalt values can roughly indicate that there are 5 ionic interactions occurring
between SbO4L and thrombin. This combined with the sulfation level of approximately 1-2
sulfates per monomer indicates that the active binding portion of SbO4L could be limited to a
simple dimeric-pentameric lignin molecule.
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Figure 31. Effect of salt on SbO4L binding to thrombin. (A) Decrease in fluorescence intensity
was observed as fFPR-Thrombin was titrated with SbO4L at various concentrations of sodium
chloride. The change in fluorescence calculated as a ratio to the initial fluorescence was plotted
against the concentration of SbO4L and fitted to the quadratic equation to obtain the
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dissociation constant under the various conditions. (B) A linear relationship of log K D vs Log
[NaCl] for SbO4L interaction with thrombin yields an R2 of 0.98. The slope of the line provides
information on the Γsalt which indicates that there are approximately 5 ionic interactions
involved between SbO4L and thrombin.
Table 6. Dissociation Constant of SbO4L at various concentrations of NaCl. The 100mM
KD is comparable to the IC50 obtained as the IC50 experiment is performed at similar salt
concentration.

NaCl (mM)

KD (μM)

100

0.02  0.01

125

0.12  0.02

150

0.17  0.03

200

0.89  0.06

Table 7. A comparison of the Γsalt values of SbO4L to various thrombin binding ligands
from literature. It can be seen that SbO4L shows comparable salt interactions to exosite 2
binding ligands as compared to exosite 1 binding ligands.
Γsalt (NaCl)

Ligand
Hirugen

-1.06 ± 0.02207

Thrombomodulin ± Chondroitin Sulfate

-4.8 ± 0.6207

Thrombomodulin – Chondroitin Sulfate

-2.2 ± 0.4207

Glycocalicin (Soluble GPIbα)

-4.2 ± 0.279
-4.6  0.4208

Heparin

-4.8 0.6 209

SbO4L

-5.0  0.2
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Thrombin Inhibition by SbO4L can be Reversed by Protamine
A major advantage of heparin therapy is its amenability to protamine-based reversal. It is
also one of the reasons why fondaparinux continues to suffer because its iatrogenic bleeding is
difficult to reverse rapidly. To test whether SbO4L inhibition of thrombin can be reversed, we
studied the recovery of thrombin activity following successive introduction of protamine. Figure
32 shows the thrombin recovery profile with varying levels of protamine after achieving 50%
inhibition with SbO4L. The protamine-mediated recovery profile essentially mirrors the SbO4Linduced inhibition profile. More importantly, the level of recovery is quantitative at high enough
protamine concentrations. Further, the recovery was instantaneous as no extended incubation
was necessary to observe reversal. The concentration of protamine necessary to recover 50%
thrombin activity, i.e., RC50, could be calculated using an equation similar to the logistic
equation 4 used for inhibition studies and found to be ~0.1 μg/ml, a concentration equivalent to
the IC50 for SbO4L inhibition of thrombin.
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Figure 32. Protamine-mediated reversal of SbO4L inhibition of thrombin. Recovery of thrombin
activity at varying levels of protamine following 50% inhibition by SbO4L was measured
through the Spectrozyme TH hydrolysis assay at pH 7.4. Solid line represents non-linear fit of
the data by a logistic function similar to equation 4 to obtain the RC50, the concentration of
protamine necessary to recover 50% thrombin activity.

3.4 Discussion
Current anticoagulation therapy largely involves heparin, heparin derivatives and vitamin
K antagonists. While being inexpensive, such therapies suffer from complications such as
bleeding and heparin-induced thrombocytopenia arising due to their non-selectivity in activity.210
Alternative small molecule inhibitors of coagulation enzymes such as dabigatran against
thrombin and rivaroxaban against factor Xa have also been proposed for therapy. But such
treatments still have bleeding complications and safety concerns over long term use and are
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expensive in comparison to heparins.211,212 The ideal anticoagulant when compared to these
would therefore have to be highly selective, with little or no side-effects, while also being
inexpensive.
Thrombin, being a central enzyme in the coagulation cascade, would seem to be an ideal
target for preventing coagulation. Yet due to its plastic nature, active site inhibitors of the
enzyme have been unable to protect the haemostatic system from bleeding risks, and therapies
targeting thrombin require frequent monitoring. On the other hand, targeting thrombin’s
allosteric exosites in a manner similar to nature could potentially lead to a better anticoagulant
for clinical purposes.213
The design for a homogenous direct thrombin inhibitor which acts on thrombin via
allosteric mechanisms has originated in the form of sulfated low molecular weight lignins.183
Originally, such sulfated lignins were designed to mimic heparin.182 However, heparin is devoid
of any direct inhibition of thrombin, i.e. it requires antithrombin to inhibit thrombin. In contrast
these sulfated lignins were found to inhibit thrombin by targeting exosite 2 without any need of
serpin.183 Hence the mechanism of such parent lignins was unique and not comparable to any
natural ligand. Additionally, such chemoenzymatically synthesized lignins were complex
heterogeneous mixtures with respect to their inter-monomeric linkages. As a result, these
polymers were not selective for a single enzyme and were found to be active against a number of
other heparin binding serine proteases (Table 1).185,186 The predominant inter monomeric linkage
found in such lignins is generally β-O4 type. Thus the idea arose that a chemically synthesized
homogenous lignin polymer with the β-O4 type inter-monomeric linkage would possibly be
more selective and potent as a thrombin inhibitor. The synthesis of such a molecule could further
provide insight into the novelty of the mechanism.
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We synthesized SbO4L using simple 7-step protocol with readily available and
inexpensive starting materials. The β-O4 lignin polymer can be synthesized easily in two steps
from the monomer 5. To generate sufficient quantities of SbO4L for all studies, the key
intermediate 5 was produced in larger quantities using a new 4-step, mild synthetic route which
can be utilized in the future for creating modifications.196,197 Polymerization of monomer 5
followed by reduction gave purified β-O4 lignin using methods described before.198,199
Ultimately, the sulfation of the lignin so synthesized yielded SbO4L. The SbO4L so produced
was characterized utilizing elemental analysis and SEC, while batch-to-batch reproducibility of
the synthesis to produce biosimilars was established using RPIP-UPLC-MS fingerprinting and
thrombin inhibition assay. Overall, the synthetic procedure yielded highly reproducibly active
SbO4L which can be scaled up for the most part.
SbO4L was found to inhibit thrombin and plasmin with high potency and selectivity over
other serine proteases. Such selectivity is remarkable when compared to previous
chemoenzymatically synthesized lignins (Table 1). While inhibition of plasmin may seem to
thwart the anticoagulant potential of SbO4L, free plasmin is not normally present in blood and is
often neutralized by α2-antiplasmin and α2-macroglobulin, which ensures buildup of plasmin for
antifibrinolytic activity takes several hours.214,215 As a result the antifibrinolytic effect of SbO4L
may not be observed if it successfully prevents clot formation in the first place. Moreover,
SbO4L might be capable of providing better prophylactic anticoagulation by preventing the
fibrinolysis of already formed clots, thereby preventing bleeding but simultaneously preventing
new clot formation. Clinically, this dual mechanism of anticoagulation and plasmin inhibition by
SbO4L could prove useful in disseminated intravascular coagulation (DIC) which can be caused
by sepsis, surgery or trauma, cancer and complications during pregnancy or childbirth. 185,216,217
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DIC manifests when there is widespread clotting due to thrombin mediated coagulation and
paradoxical bleeding due to plasmin mediated fibrinolysis.
Mechanistically SbO4L was found to inhibit thrombin without the help of antithrombin
III. While addition of antithrombin III does not result in an increased potency, it does increase
the efficacy (indicated by the decrease in YM and Y0 values) of SbO4L mediated thrombin
inhibition. These results suggest an independent mechanism of SbO4L and antithrombin against
thrombin. In comparison parent LMW lignins showed increased potency in the presence of
antithrombin III.191 Thus SbO4L is mechanistically more selective than parent lignins.
Since thrombin plays vital anticoagulant functions by binding to thrombomodulin, we
investigated if SbO4L abrogates such antithrombotic action by testing it against thrombomodulin
thrombin complex for physiological substrate activated protein C. Our results indicated clearly
that SbO4L is a more potent inhibitor of free thrombin compared to the anticoagulant form of
thrombin. Thus SbO4L could be used to shift the population of thrombin in the blood from a net
procoagulant state to thrombomodulin bound anticoagulant state. Furthermore, combining
SbO4L with thrombomodulin as a therapy for DIC could prove very useful in management of the
coagulopathy.
SbO4L inhibits a variety of types of thrombin from different species as well as thrombin
degradation products in an equipotent manner. This is important because significant structural
differences exist between different types of thrombin among species and thrombin degradation
products. For example, in place of Asp222 in the sodium binding site, murine thrombin has a
Lys222 which results in a charge reversal substitution in the Na+ binding loop.218 This allows the
Nζ atom of the Lys222 of murine thrombin to mimic the positive charge of the Na+ and mimic
the cation, thereby locking the enzyme in a “fast-form” which is also believed to be the
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procoagulant form. SbO4L’s equipotent inhibition of murine thrombin is a sign that the molecule
is capable of inhibiting the fast-form of thrombin. This is also important from a translational
point of view to show that SbO4L based inhibition can possibly be tested in mouse thrombosis
models. Bovine thrombin on the other hand shows differences in the Tyr-Pro-Pro-Trp segment of
the 60-loop, Glu-192 and catalytic residues His57 and Ser195.219 SbO4L inhibition of bovine
thrombin further confirms that the molecule possibly binds at the more conserved exosite 2
rather than the structurally different active site when compared to human thrombin. Human γthrombin is a degradation product of human α-thrombin in which the exosite 1 is disordered.220
As a result of this γ-thrombin has a disrupted capability for cleaving physiological substrate
fibrinogen to form a clot.221 SbO4L shows potent inhibition of γ-thrombin, albeit with 2-fold
lower activity. This was important from future translational research in establishing SbO4L
antiplatelet activity. SbO4L was also found to inhibit thrombin while using fibrinogen as a
substrate with comparable potency to the chromogenic substrates. This is fundamental for
development of any anticoagulant to ultimately be useful with physiologically relevant
substrates.
The mechanism by which SbO4L inhibits thrombin was deduced by an amalgamation of
Michaelis-Menten kinetics, competition and mutagenesis studies. Michaelis-Menten kinetics data
showed that SbO4L inhibition is non-competitive with chromogenic substrate and is therefore
binding at an allosteric site – away from the active site of the enzyme. Binding of SbO4L was
found to induce allosteric change in the active site conformation as was confirmed using
collisional quenching.
Competition with known exosite 2 ligands unfractionated heparin (UFH) and GPIbα and
exosite 1 ligand hirugen peptide further help locate SbO4L binding at exosite 2 of thrombin.
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Using specific single and triple mutants of exosite 2 basic residues, it was concluded that SbO4L
requires Arg233, Lys235 and Lys236 of thrombin exosite 2 for binding. These residues are
known to be vital for the interaction of sulfated tyrosine-rich anionic peptide (STRAP) of GPIbα,
a platelet surface glycoprotein, with thrombin.79,115-118 Structurally this STRAP resembles the
aromatic-sulfate strategy observed in SbO4L and hence it can be imagined that the binding sites
of the two molecules are overlapping. Mechanistically, it is known that GPIbα can inhibit
thrombin’s fibrin formation activity via binding to exosite II, which is comparable to SbO4L.79,80
However, this site of thrombin has never been explored previously from a potential drugtargeting perspective.
Characterizing the binding nature of SbO4L to thrombin, using a salt dependant study of
binding affinity helped in identifying that the nature of the interactions has a high ionic
component similar to other known exosite 2 ligands (Table 8). This study indicated that
approximately 5 sulfate groups were involved in the binding of SbO4L to thrombin. This result
when taken together with the elemental and size exclusion chromatography data, suggests that
the actual pharmacophore moiety of SbO4L may be a simple dimeric-pentameric lignin
molecule.
Lastly, we have demonstrated the possibility of reversing SbO4L activity using FDA
approved protamine in an in vitro assay. From a therapeutic point of view, these results suggest
that an antidote for SbO4L is already present in the market. Hence establishing safety windows
should be easier knowing that the antidote is at hand.
Overall, we have shown a significant step forward from parent LMW lignins in terms of
homogeneity, ease and reproducibility of synthesis, potency and selectivity with the development
of SbO4L. Furthermore, we have been able to compare the mechanism of SbO4L with an
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endogenous ligand in the form of GPIbα. Our in vitro studies have helped us identify a potential
pathway to develop smaller and more homogenous molecules to target the GPIbα site by
mimicking SbO4L. However, further validation of targeting this site was required in higher order
assays such as in plasma, whole blood and even in vivo.
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Chapter 4: Advanced Level Characterization of Antithrombotic Potential of SbO4L
4.1 Introduction
Annually, more than 100 publications present data on thrombin inhibitors, yet only a
small percentage of the publications involve new chemistry.3 The majority of small molecules
out of these target the active site of thrombin. This trend is gradually changing as allosteric
inhibitors are gaining more importance. Targeting the active site results in complete knockout of
the enzyme and hence results in complicated clinical outcomes. As a result there is a large
amount of research being performed on determining the efficacy, pharmacology, toxicology and
clinical outcomes of thrombin inhibitors.
SbO4L, a completely synthetic sulfated β-O4 lignin, was found to be a potent and
selective inhibitor of thrombin when tested in vitro. We established that the mechanism involved
in SbO4L mediated anticoagulation was unique in that it mimicked the platelet receptor GPIbα.
Similar to GPIbα, SbO4L is known to reduce the catalytic efficiency of thrombin towards
fibrinogen cleavage by binding to exosite 2 of thrombin.79 Competition and mutagenesis data
highlighted the fact that the binding site was identical to the GPIbα-STRAP. Physiologically
thrombin binding to GPIbα is vital for procoagulant platelet aggregation and activation
functions.81,222
For any new mechanism of anticoagulation to be clinically relevant, it has to translate
well from in vitro assays to ex vivo and finally to in vivo tests. Therefore, it is vital for us to

105

establish that targeting the GPIbα site on thrombin by SbO4L could yield a potentially useful
antithrombotic, which is effective even in vivo. Additionally, we reasoned that the fact that
SbO4L could compete and mimic GPIbα for binding to thrombin may result in dual
pharmacological actions in ex vivo and in vivo systems. We hypothesized that SbO4L could
possibly act as antithrombotic using a dual mechanism, wherein, (a) it could provide an allosteric
direct inhibition of thrombin to produce anticoagulant activity; and (b) it could compete with
GPIbα from binding to thrombin and thereby producing antiplatelet activity as well (Figure 33).
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Figure 33. Dual mechanism of antithrombotic action by SbO4L in advanced assays. Thrombin is
capable of cleaving fibrinogen using its active site, and binding to GPIbα using its exosite 2.
Binding of GPIbα to exosite 2 causes an allosteric change within the active site. SbO4L binding
to thrombin at exosite 2 in a manner similar to GPIbα could possibly induce allosteric inhibition
of thrombin towards catalytic conversion of fibrinogen resulting in anticoagulant activity, while
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also providing a competitive inhibition of thrombin binding to GPIbα resulting in antiplatelet
activity.

To verify if our hypothesis of dual mechanism holds true in complex systems, we first
tested the anticoagulant and antiplatelet activities separately in plasma and platelet rich plasma
using APTT/PT assays and platelet aggregation/activation assays respectively. We then sought to
investigate the properties of this dual mechanism in tandem by using whole blood with
Hemostatic Analysis System and Thromboelastography tests. Finally we tested if SbO4L could
provide sufficient antithrombotic effect in vivo in several mouse thrombosis models.

4.2 Experimental Procedures
Materials
Pooled normal human plasma for coagulation assays was purchased from Valley Biomedical
(Winchester, VA). Activated partial thromboplastin time (APTT) reagent containing ellagic acid,
thromboplastin-D and 25 mM CaCl2 were obtained from Fisher Diagnostics (Middletown, VA).
Thromboelastograph® Coagulation Analyzer 5000 (TEG®), disposable cups and pins, and 200
mM stock CaCl2 were obtained from Haemoscope Corporation (Niles, IL). All other chemicals
were analytical reagent grade from either Sigma Chemicals (St. Louis, MO) or Fisher
(Pittsburgh, PA) and used without further purification.
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Plasma APTT/PT Assay
Clotting times were determined in a standard 1-stage recalcification assay with a BBL
Fibrosystem fibrometer (Becton-Dickinson, Sparles, MD), as reported previously.183,184 For
prothrombin time (PT) assays, 10 µl of SbO4L (or a reference agent) was mixed with 90 μl of
citrated human plasma, incubated for 30 s at 37°C, followed by the addition of 200 µl of prewarmed thromboplastin. For activated partial thromboplastin time (APTT) assays, 10 µl of
SbO4L solution was mixed with 90 µl citrated human plasma and 100 µl 0.2% ellagic acid.
Clotting was initiated by adding 100 µl of 25 mM CaCl2. Each experiment was performed in
duplicate. The averaged data was plotted and a quadratic trend line was used to calculate the
concentration of SbO4L that doubles the clotting time (2×APTT or 2×PT).

Effect of Serum Albumin on the Inhibition Efficacy of SbO4L
The effect of serum albumin on SbO4L inhibition of thrombin was tested by assessing residual
thrombin activity in 20 mM Tris-HCl, 100 mM NaCl, 2.5 mM CaCl2, 0.1% PEG 8000, pH 7.4,
containing BSA at four different concentrations (0, 1, 2.5 and 10 mg/ml). Briefly, 5 μl of 2.3
mg/ml SbO4L was incubated with 185 μl of each of these buffers in a 96-well plate at 37°C in
duplicate. To this was added 5 μl of 240 nM thrombin, incubated for 10 minutes and 5 μl of 5
mM Spectrozyme TH added to measure the residual active thrombin.
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Preparation of Platelet Rich and Platelet Poor Plasma
Whole human blood was collected from healthy volunteers and used to prepare platelet rich
plasma (PRP) by spinning at 70 x g for 10 minutes and platelet poor plasma (PPP) by spinning at
900 x g for 10 minutes. The platelet count in the PRP was adjusted to 220,000 platelets / ml
using the PPP and the material was used within 4 hours of withdrawal.

Platelet Aggregation Assay
The effects of SbO4L on γ-thrombin induced platelet aggregation were studied using the
Chrono-log Model 700 Optical Lumi-Aggregometer (Chrono-Log Corporation, Havertown, PA).
Briefly, 250 μl of PRP was incubated with SbO4L (0-535 μg/ml) for 3 minutes at 37°C.
Aggregation was initiated by using either 152nM or 76nM of γ-thrombin. Aggregation was
monitored using the optical settings of the aggregometer for at least 6 minutes.

ATP Secretion Assay
The effects of SbO4L on α-thrombin mediated ATP secretion were studied using the Chrono-log
Model 700 Optical Lumi-Aggregometer (Chrono-Log Corporation, Havertown, PA) following
manufacturers protocol with slight modification. Briefly 450 μl of PRP was incubated with 50μl
of CHRONO-LUME reagent containing Luciferase enzyme and 0-5μl SbO4L (0-248 μg/ml final
concentration in the cuvette) for 3 minutes at 37°C. One unit of CHRONO-PAR thrombin (αthrombin) was added to the solution and the luminescence was monitored for at least 6 minutes.
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An ATP standard of 2 nmoles was run separately in similar conditions to standardize the
luminescence and obtain quantitative results of the amount of ATP released in each run.

Haemostatic Analysis System
Analysis of platelet function and clot structure was performed using the HASTM from
Hemodyne, Inc., Richmond, VA, as reported earlier.184 A mixture of 700 μl of citrated whole
blood and 10 μl SbO4L (or water as control) was co-incubated at room temperature for 5 minutes
and then placed in a disposable cup. To initiate clotting, 50 μl of 150 mM CaCl 2 was added. As
the clotting proceeds, platelets attach to surfaces generating tension within the fibrin meshwork
from which platelet contractile force (PCF) and clot elastic modulus (CEM) parameters are
obtained in an automated manner.

Thromboelastography TEG Analysis of Clot Formation
TEG assays were performed as reported earlier.184 Briefly, the assays were initiated by
transferring 20 μl of 200 mM CaCl2 into the HaemoscopeTM disposable cup, oscillating through
4°45’ angle at 0.1 Hz, followed by the addition of a mixture of 340 μl of sodium citrated whole
blood containing 10 μl SbO4L or water (control) at 37°C. This recalcification initiates clot
formation in the TEG coagulation analyzer, which operates until all data collection (R, K, α and
MA) is computed in an automated manner.
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In Vivo FeCl3 Carotid Artery Thrombosis Model
Procedures involving mice were approved by the Institutional Animal Care and Use Committee
of Vanderbilt University and have been previously reported.223,224 Wild type C57Bl/6 mice were
anesthetized with 50 mg/kg IP pentobarbital. SbO4L (0, 100, 300, 500 or 1000 μg in 100 μl
phosphate buffered saline) was infused into the right internal jugular vein. Five minutes after
infusion, the right common carotid artery was exposed and fitted with a Doppler flow probe
(Model 0.5 VB, Transonic System, Ithaca, NY). Thrombus formation was induced by applying
two 1 x 1.5 mm filter papers (GB003, Schleicher & Schuell, Keene, NH) saturated with FeCl3
(3.5% solution) to opposite sides of the artery for three min. After washing the site of injury with
PBS, flow was monitored for 30 min. Mice were sacrificed by pentobarbital overdose after
conclusion of the experiment, while under anesthesia.

In Vivo Rose-Bengal Laser Thrombosis Model
In vivo testing using Rose Bengal thrombosis model was adapted from previously reported
literature.224 C57Bl/6 mice were anesthetized as above and 500 μg of SbO4L in 100 μl phosphate
buffered saline was infused into the right internal jugular vein. Five minutes after infusion, Rose
Bengal (75mg/kg) was infused through the internal jugular vein, and the carotid artery was
illuminated with a 1.5 mW 540 nm laser (Melles Griot, Carlsbad, CA) positioned 6 cm from the
artery. Flow was monitored for 120 min. Mice were sacrificed by pentobarbital overdose after
conclusion of the experiment, while under anesthesia.
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Tail Bleeding Time
Tail bleeding assays offer a measure of hemostasis in the presence of SbO4L. To perform the tail
bleeding assay, the mice are anesthetized as mentioned above, following which the animal is
placed on a 37 °C heating pad. 100 μl SbO4L is then injected into a lateral vein using a 1 ml
tuberculin syringe fitted with a 27-gauge needle. The tail is trasected with a scalpel just above
the tip. The bleeding tail is immersed in a centrifuge tube filled with PBS and kept at 37 °C. The
animal is observed for up to 1000 seconds and the time required to cease the bleeding is noted.
Mice are sacrificed prior to recovering from bleeding.

4.3 Results
SbO4L Prolongs Clot Formation in Plasma APTT/PT Assays
Prothrombin (PT) and activated partial thromboplastin times (APTT) are traditional
measures of the anticoagulation state of human plasma. Figure 34 shows the variation in plasma
PT and APTT in the presence of SbO4L. A significant concentration-dependent prolongation of
clotting times was observed suggesting good anticoagulation potential. A 2-fold increase in PT
required 68 μg/ml of SbO4L, corresponding to 7.5 μM, which is significantly lower than that
needed for a generic LMWH (142 μg/ml, 31.6 μM) and a clinically used LMWH (enoxaparin,
339 μg/ml or 75 μM).184 Likewise, a two-fold increase in APTT required 20 μg/ml (2.2 μM) of
SbO4L, which compares favorably with a concentration of 5.9 μg/ml (1.3 μM) for generic
LMWH in inducing plasma anticoagulation.
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Figure 34. Prolongation of clotting time as a function of SbO4L concentration in either the
prothrombin time (PT) or the activated partial thromboplastin time (APTT) assay. The solid lines
are trend lines, and not exponential fits.

SbO4L Inhibition of Thrombin is Abrogated in the Presence of Albumin
Despite this high potency (comparable to enoxaparin), SbO4L displays a loss of ~100–
340-fold in potency in human plasma from that in in vitro enzyme systems. To assess the basis
for this difference, we studied the effect of serum albumin on the effectiveness of SbO4L. Figure
35 shows the change in relative thrombin activity in the presence of fixed concentration of
SbO4L and varying concentrations of bovine serum albumin (BSA), a surrogate for its human
counterpart. In the absence of BSA, thrombin’s hydrolytic activity was 22% ([SbO4L] = 0.42
μg/ml), which was found to increase to 56, 59 and 72% in the presence of 1, 2.5 and 10 mg/dl
BSA, respectively. This suggests that the presence of BSA results in a significant drop in
inhibitor potency probably arising from non-specific sequestering of SbO4L. Interestingly, a
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maximal thrombin activity of ~75% is reached suggesting that some SbO4L remains free, and
therefore inhibitory, at high enough plasma albumin concentration.
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Figure 35. The effect of serum albumin on the thrombin inhibition potential of SbO4L. Solid line
to the data represents a rectangular hyperbolic fit to the data to derive the maximal thrombin
activity at limiting concentrations of BSA. The dotted line represents the maximal thrombin
activity. See text for details.

SbO4L Potently Inhibits Platelet Aggregation in Platelet Rich Plasma (PRP)
The idea that targeting GPIbα could also be utilized to prevent platelet aggregation and
activation for antithrombotic potential has been around.159 Since SbO4L binds to identical
binding site as GPIbα and competes with it, we tested the effects our molecule had on thrombin
mediated platelet aggregation. An optical method to monitor platelet aggregation was used which
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employs an increase in transmittance of platelet rich plasma (PRP) as a signal for aggregation
under high sheer. The use of γ-thrombin was done so as to monitor purely platelet aggregation
activity without interference by fibrin mesh formation (Figure 36).123 Two different test
concentrations of γ-thrombin were used as the trigger and it was noticed that as the concentration
of the activating thrombin was lowered from 152 nM and 76 nM (Figure 37A and 37B
respectively), the amount of SbO4L required to prevent platelet aggregation was also reduced
from 321 μg/ml to 105 μg/ml. Furthermore at all doses of SbO4L, a unique platelet response was
observed in which the platelets would initiate aggregation no matter how high the concentration
of SbO4L, but after reaching its peak aggregation would start showing a reduced
transmittance(Figure 37C). This could be a result of change of shape of the platelets or
disaggregation.

α-thrombin

γ-thrombin

γ- thrombin + SbO4L

Figure 36. A comparison of α-thrombin and γ-thrombin as platelet aggregation initiators. αthrombin causes the formation of a fibrin mesh which traps the platelet aggregates. In
comparison, γ-thrombin creates aggregates without any formation of fibrin network. The last
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image shows that in the presence of SbO4L, γ-thrombin is incapable of forming platelet
aggregatres.
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Figure 37. Variation in level of platelet aggregation as a function of the concentration of
SbO4L. Platelet aggregation was measured in the presence of varying concentrations of SbO4L
using either 152 nM (A) or 76 nM (B) γ-thrombin as the trigger. Representative traces (C) of
human platelet rich plasma (PRP) aggregation induced by 76 nM γ-thrombin in the presence or
absence of 217 μg/mL SbO4L. Aggregation was monitored by following time dependence of
transmittance at 620 nm following addition of γ-thrombin.
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SbO4L Potently Prevents ATP Secretion by Platelets in PRP
To assess platelet activation, ATP secretion was monitored using luminescence method
of monitoring ATP release by using luciferase enzyme under high sheer. Use of α-thrombin was
possible in this assay due to the fact that fluorescence detections were independent of fibrin
formation. It was observed that 248 μg/ml of SbO4L potently inhibited ATP release by 85%
when 1 unit of α-thrombin was used to trigger platelet activation (Figure 38), and a dose
dependant increase in ATP release was observed with decrease in SbO4L.

1.2

ATP Secretion
(nmoles)

1
0.8
0.6
0.4
0.2
0

248

174

149

139

124

100

0

[SbO4L] (μg/ml)
Figure 38. Reduction in the level of ATP released by platelets in the presence of varying levels of
SbO4L. ATP release by platelets was monitored using luminescence in the presence of luciferase
enzyme.
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SbO4L Inhibits Platelet Prothrombotic Function in Whole Blood when Analyzed using
Hemostasis Analysis System (HAS)
To further assess the whole blood anticoagulant potential of SbO4L, we utilized HAS™,
which evaluates platelet contribution to clot formation (Figure 39).184 This technique evaluates
clot structure through the measurement of clot elastic modulus (CEM), which is the ratio of
stress induced by platelets to strain arising from the change in clot thickness. The technique also
provides information on contractile forces between platelets, i.e., the platelet contractile force
(PCF), that adhere to surfaces and restrict relative movement of two cups. PCF depends on the
platelet number, their metabolic status, presence of thrombin inhibitors and degree of GPIIb/IIIa
exposure.225 On the other hand, CEM depends on the clot micro-structure, fibrinogen
concentration, and thrombin formation rate. It has been suggested that PCF and CEM changes
can be correlated with susceptibility to bleeding and/or thrombotic tendency.
SbO4L affects PCF and CEM in a dose-dependent manner (Table 8). As the
concentration of SbO4L increases from 0 to 74 μg/ml, the PCF and CEM decrease from 8.0 to
0.7 kDynes and 18.3 to 0.6 kDynes/cm2, respectively (Figure 39A and 39B, Table 8). When
comparisons are made with enoxaparin, strikingly similar results are observed except for the
range of concentration used for the clinically used anticoagulant. Whereas PCF value of 0.7 was
achieved at 74 μg/ml (8.1 μM) for SbO4L, it was achieved at 2.0 μg/ml (444 nM) for enoxaparin
suggesting a ~37-fold better potency for the latter on weight basis and ~18-fold better potency on
molar basis. These results further confirm that SbO4L mediated targeting of the GPIbα site of
thrombin exosite II could be useful in creating future antithrombotics.
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Figure 39. Comparison of the effect of SbO4L on platelet function in whole blood using
hemostasis analysis system (HAS™). (A) and (B) show the change in platelet contractile force
(PCF) and clot elastic modulus (CEM), respectively, with time at various fixed concentrations of
SbO4L (0–74 μg/ml).
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Table 8. Hemostasis Analysis System Parameters for SbO4L Anticoagulation in
Comparison to Enoxaparin.
Hemostasis Analysis*

SbO4L

Enoxaparin

[Conc]
(μg/ml)

TOT*
(min)

PCF*
CEM*
(kDynes) (kDynes/cm2)

0

6.3

8.0

18.3

0.07

5.1

7.3

12.0

7.4

6.6

5.8

6.3

37

11.3

3.3

3.9

74

13.6

0.7

0.6

0

3.6

7.6

21.6

0.7

5.2

5.3

15.1

1.0

9.1

3.6

12.7

1.6

11.0

2.8

8.5

2.0

12.5

0.9

2.9

*Analysis was performed using Hemostasis Analysis System (HAS) on human whole blood as
described in ‘Experimental Procedures’. Parameters deduced from this analysis included TOT
(thrombin onset time), PCF (platelet contractile force) and CEM (clot elastic modulus).

SbO4L

Inhibits

Thrombus

Formation

in

Whole

Blood

when

Analyzed

using

Thromboelastography (TEG)
To evaluate SbO4L as an anticoagulant in whole blood, we employed TEG®, which is
quite often used to monitor anticoagulation therapy with LMWH.184 TEG assesses the nature of
physical forces within a clot, which are dramatically affected by the presence of an anticoagulant
in blood. In a nutshell, the clot formation in TEG is recorded as a force transduced on a pin at
the center of a blood-containing cup. Several parameters are evaluated from this force
measurement including maximum amplitude (MA), the shear elastic modulus (G), the reaction
120

time (R) and the angle α. MA and G are measures of clot stiffness, while R and α are measures of
the rate of clotting. Figure 40 shows the output obtained from the instrument.
Table 9 shows the change in R, α, MA and G parameters as a function of the
concentration of SbO4L. Briefly, as the concentration of SbO4L increases from 0 to 152 μg/ml,
R increases from 7.7 to 25.9 min, while α decreases from 56° for normal blood to 22° indicating
that the kinetics of fibrin polymerization and network formation is significantly depressed by the
presence of SbO4L. Enoxaparin behaves in a similar manner, except that its effective
concentrations range from 1–5 μg/ml. Likewise, SbO4L reduces MA and G in a manner similar
to enoxaparin (Table 10), except for the ~30-fold better potency of the latter (~15-fold molar
basis).
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17.1 μM
[TKS]O = 0 μM
0.02 μM
1.7 μM
[SbO4L] = 0 μg/ml 0.15 μg/ml 15.2μg/ml
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Figure 40. Effect of SbO4L on whole blood hemostasis using Thromboelastography (TEG).
Insert on the right shows different parameters obtained from TEG study. SbO4L shows a dose
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dependant change in clotting parameters MA, R, α and G, with a doubling in clot initiation time
(R) at 76.5 μg/ml.

Table 9. Thromboelastography Parameters for SbO4L Anticoagulation in Comparison to
Enoxaparin
Thromboelastography*

SbO4L

Enoxaparin

[Conc]
(μg/ml)

R*
(min)

α*
(degs)

MA*
(mm)

G*
(kDynes/cm2)

0

7.7

56.0

61.0

7821

0.15

8.9

50.5

50.5

7658

15.2

13.2

42.5

57.0

6628

76.5

16.9

43.0

55.5

6236

152

25.9

22.0

41.5

3547

0

7.0

59.0

56.5

6457

1.35

8.0

49.0

51.0

5204

2.7

11.5

43.0

47.0

4434

3.4

14.0

41.0

46.0

4260

4.5

17.0

31.5

42.0

3621

*Analysis was performed using thromboelastography (TEG) on human whole blood as described
in ‘Experimental Procedures’. Parameters deduced from this analysis included R (time to clot
initiation), α (angle), MA (maximum amplitude) and G (shear elastic modulus).

SbO4L shows potent Antithrombotic Action in FeCl3 Thrombosis Model, Rose Bengal Laser
Injury Model and Tail-Bleeding Time In Vivo in Mice
The antithrombotic effect of SbO4L was tested in two well-characterized arterial
thrombosis models following procedures previously reported.223,224 Exposure of the carotid
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artery of wild type mice to a 3.5% solution of FeCl3 results in formation of an occlusive plateletrich thrombus within 15 minute (Figure 41A). SbO4L prevented occlusion of the arteries of
some mice at doses of 250 or 500 mg, with all mice protected from vessel occlusion at a dose of
1000 mg (Figure 41A and 41B). FeCl3 is thought to produce a severe injury accompanied by
desquamation of vascular endothelium.
The effects of a 500 mg dose of SbO4L were also tested in a model in which vessel injury
is produced by exposure to laser light after infusion of the dye Rose Bengal. The carotid artery is
surgically made accessible and the laser light is shined upon it. The laser light converts the dye to
free radicals, which result in vessel occlusion with a platelet-rich thrombus in 44.7  6.5 minutes
in vehicle treated controls. Occlusion occurred in 76  21.3 minutes in animals treated with 500
μg SbO4L.
The effective dose of SbO4L that prevented thrombosis in the FeCl3 model (1000 μg),
also caused a marked prolongation of the tail bleeding time, from ~110 s to > 1000 s. The total
blood loss was also higher from 50 μl to 120 μl.
Note- This work was performed by the Dr. David Gailani Laboratory (Vanderbilt University
Medical Center, Nashville, TN)
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Figure 41. In vivo anticoagulant effect of SbO4L as observed in C57BL/6 mice. (A)
Measurement of arterial blood flow using Doppler flow probe, as a representation of the
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formation of occlusive platelet-rich thrombus in the carotid artery of mice with the application of
3.5% FeCl3 with a prior injection of either 100 or 1000 μg of SbO4L. (B) Dose-dependent
decrease in arterial clot formation in a study with 4-8 C57BL/6 mice shows that SbO4L is most
effective at a dose of 1000 μg.

4.4 Discussion
In order to test if the in vitro efficacy holds true ex vivo and in vivo, we put SbO4L
through an array of assays in ascending order of complexity. Furthermore, such assays helped in
characterizing the dual mechanism of antithrombosis demonstrated by SbO4L, which is truly
unique in comparison to any known molecule.
First, to test the anticoagulant activity, SbO4L was tested in classical APTT and PT
assays which are standard assays often used to test anticoagulant drugs.226,227 SbO4L was found
to double the clotting times in both the assays 20 and 68 μg/ml concentrations, which was
comparable to clinically approved LMWH Enoxaparin. More importantly since there is only a 3fold difference between 2xAPTT and 2xPT values, suggesting that in advanced systems, SbO4L
is possibly inhibiting the common pathway of coagulation involving thrombin alone, with little
side reaction more with the intrinsic pathway. These results agree well with the screening
information obtained from the in vitro tests. Interestingly, prolonging the APTT rather than PT
might be vital to prevent thrombosis and thromboembolism.228 Hence SbO4L selectivity of effect
on APTT over PT might be a boon to the molecule’s safety profile.
When the quantitative numbers of the APTT and PT are compared to the in vitro results,
there is a remarkable drop in activity (~ 100 fold). The most likely explanation is that SbO4L
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binds to albumin in the plasma. Albumin is the most abundant carrier protein present within the
blood and is known to bind almost all drugs. We successfully demonstrated that SbO4L’s in vitro
inhibition of thrombin is in fact lowered by the presence of serum albumin. The most interesting
fact was that even at high concentrations of serum albumin, SbO4L retained some thrombin
inhibitory potential. Thus it is possible that albumin binding of SbO4L might reduce the efficacy
but not completely eliminate it. Additionally, this binding might extend the duration of SbO4L
action as albumin binding may prove a useful reservoir for SbO4L.
To test our second hypothesis that SbO4L could possibly inhibit thrombin-mediated
platelet aggregation and activation by competing with GPIbα, we performed extensive platelet
aggregation and activation studies in platelet rich plasma (PRP). Platelet aggregation studied by
light transmission and activation studied by ATP secretion using luminescence are well
standardized tests used to test antiplatelet agents.229,230 We found that SbO4L was a good
antiplatelet agent at low concentrations. These results when taken together with the competition
data, support the fact that SbO4L’s competition with GPIbα could potentially abrogate thrombinmediated platelet aggregation. When given in vivo, it is highly probable that both mechanisms,
i.e., anticoagulation and antiplatelet, play a role. Further, our studies showed that the amount of
SbO4L required to thwart the platelet aggregation was related to the amount of the triggering
agent used. This could be an important observation, which might affect dosing regimens in future
studies.
SbO4L was then tested in whole blood using HAS and TEG. Whole blood is a system in
which both coagulation and platelets play a role. While the HAS system tests the platelet
functions more closely, TEG is useful to look at the coagulation parameters. Both systems are
often used to monitor and test anticoagulant and antiplatelet therapy clinically.229-231 In both, the
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HAS and TEG studies, SbO4L showed good potency comparable to the concentrations used in
the plasma and PRP assays. Furthermore, in both assays SbO4L’s potency was comparable to
clinically used enoxaparin, suggesting that SbO4L’s antithrombotic potential could be useful.
The ultimate test to check for SbO4L’s efficacy was performed using two in vivo arterial
thrombosis models. The FeCl3 mouse arterial thrombosis model has been used since 1944 to
stimulate thrombosis, and is widely used to test the efficacy of anticoagulant and antiplatelet
therapies.232 SbO4L was found to be effective at dose of 1 mg i.v. bolus and showed a dose
dependant efficacy. However, the FeCl3 induced thrombosis is a severe injury cause by an
“outside-in” mechanism on the vessel walls, which is unlike what is observed in pathological
clotting.233 We therefore also analyzed the efficacy of SbO4L using laser induced arterial
thrombosis model which is physiologically more similar to what is observed in thrombotic
disorders where the clotting occurs without damage to the vessel wall. We found SbO4L
effective at doses of even 500 μg i.v. which is comparable to all the ex vivo data that we have
obtained.
To assess the effect of SbO4L on hemostatic function, we tested the effect of the
molecule on the tail bleeding time in mice. The effective dose of SbO4L in the FeCl3 model
(1000 μg) did show a prolonged tail-bleeding time and total blood loss compared to controls.
However, this is not surprising given the molecule’s dual mechanism of action. It is known that
patients suffering from Bernard Soulier syndrome, who show defective expression of GPIb-IX-V
complex, demonstrate such phenotype as well.234 Furthermore, bleeding models only provide
information about hemostasis in response to specific type of injury, and will not necessarily
reflect the propensity to bleed, especially when the injury involves other body parts.
Additionally, it is possible that the bleeding issues could be arising from the fact that SbO4L is
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still a mixture and possibly has off-site effects elsewhere. Therefore, future smaller, homogenous
derivatives of SbO4L would need to be tested in more in vitro, ex vivo and animal models in
order to establish efficacy, safety and bleeding risks.
Overall, we have established that ex vivo and in vivo, SbO4L can act via a dual
mechanism of anticoagulation and antiplatelet action. Furthermore, such activity gives SbO4L
antithrombotic potential similar to LMWH which is clinically used. Thus targeting the GPIbα
site with more homogenous small molecules may prove to be a useful means of producing newer
antithrombotic drugs, but may require some more testing to establish safety with respect to
bleeding.
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Chapter 5: Identifying Novel Lignin Based Inhibitors and Mechanisms for Factor XIa
5.1 Introduction
As discussed in chapter 1, factor XIa (fXIa) is emerging as a useful target for
prophylactic treatments of hyper-thrombotic states.145 It is believed that developing novel
inhibitors of factor XIa could possibly prevent thrombosis, while not causing bleeding side
effects. Furthermore, an allosteric inhibitor of factor XIa could possibly fine tune this control
further.
It has been reported that the allosteric inhibition of fXIa can be brought about by large
molecules with highly charged polyanions such as dextran sulfate, heparin, hypersulfated
heparin, sulfated pentagalloyl glucoside (SPGG) and sulfated quinazolin-4(3H)-ones
(QAOs).192,194,235 Although a number of active site inhibitors have been reported, there has been
only one report on allosteric small-molecule inhibitors (<1000 Da) of fXIa.235 These are the
sulfated QAOs, that demonstrated a maximum potency of only 52 μM. This leaves room for
more potent small-molecule allosteric inhibitors for fXIa to be discovered. The sulfated QAOs
were found to bind near the heparin binding site (HBS). Sulfated QAOs are expected to display
poor bioavailability owing to their large size and high charge density. Finally, no inhibitor of
factor XIa has been approved for use as anticoagulant in the clinic.
Chemo-enzymatically synthesized LMW lignins were found to be potent inhibitors of
factor XIa with IC50 ranging from 22-176 nM (Table 1). Such lignins presented diversity in their
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inter-monomeric, linkage which resulted in lack of selectivity and were found to be potent
inhibitors of other serine proteases as well. Hence, it was necessary to fish-out structural
components from these mixtures with selective activity for specific target serine proteases.
Interestingly, the chemically synthesized SbO4L, which has only the β-O4 type inter-monomeric
linkage was found not to be a potent inhibitor of factor XIa (IC50 = 89 μg/ml or 9.6 μM). This
suggested that it is possible that some other scaffold within the chemoenzymatic LMW lignins
was more potent towards factor XIa (Figure 42).

Figure 42. Rationale for screening sulfated small molecule library to identify factor XIa
selective inhibitor. Synthetic SbO4L, which was designed from chemo-enzymatic lignins provided
selective thrombin and plasmin inhibition. Therefore, it could be possible that other scaffolds
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from the parent lignins have high selectivity for other enzymes for which the chemo-enzymatic
lignins showed good potency. One such enzyme of interest is factor XIa. We therefore wanted to
explore possibilities for finding a factor XIa selective inhibitor through library screening of
sulfated small molecules enriched in the β-5 type linkage mimetics in the form of the benzofuran
molecules.

In order to find such a selective inhibitor lead molecule, the Desai Lab decided to screen
a library of sulfated aromatic small molecules that have been previously synthesized in our
laboratory. A library of 65 molecules (Figure 43) was tested based on various scaffolds including
sulfated flavonoids,236-240 sulfated tetrahydro-isoquinoline,241-243 sulfated quinazolinone,235
sulfated benzofurans,187-189 and other sulfated small molecules.242,244 As a group, the library
consisted of at least 12 different scaffolds allowing for a diverse range of structures to be
profiled. In particular, this library was enriched in the benzofuran scaffold, which is expected to
mimic the β-5 type linkage found in lignins and therefore explore the possibility of finding new
lignin based inhibitors of factor XIa.187-189 Our initial screen, followed by defined inhibition
profiles identified a number of benzofuran dimers and trimers with potent inhibition of factor
XIa (Table 10). In particular, molecule 24 showed highest potency at sub-micromolar
concentrations (IC50 = 0.82 μM) and was 8-fold more selective for factor XIa over thrombin
(IC50 = 5.8 μM).189
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Figure 43. Library of sulfated small molecules (SSMs).
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Table 10. Inhibition Parameters of Sulfated Small Molecules (SSMs) against factor XIa.
SSM No.

IC50 (μM)*

YM*

Y0 *

HS*

15

9.7 ± 0.3

102±2

4±4

6.9±1.2

21

7.5 ± 0.6

95±3

0±2

1.9±0.3

23

14.9 ± 0.3

94±1

7±1

5.2±0.4

24

0.82 ± 0.02

99±2

0±1

3.8±0.3

25

47.2 ± 0.9

99±2

3±2

6.6±0.8

27

6.4 ± 0.1

99±2

2±1

11.7±1.5

28

29.9 ± 0.8

103±2

10±2

6.4±0.9

29

384 ± 38

98±4

0±1

1.9±0.4

30

29.9 ± 0.5

100±2

3±2

6.9±0.7

32

99 ± 13

101±5

0±1

1.3±0.2

61

109 ± 2

96±1

0±1

6.2±0.5

63

122 ± 3

98±2

0±1

6.0±0.9

* Error bars represent ± 1 S.E.
**Work reported in Argade, M; MS Thesis, Titled: Discovery and biophysical characterization
of allosteric inhibitors of factor XIa (FXIa). (2012).

The affinity for 24 was found to be similar to the IC50 with a KD of 1.2 ± 0.3 μM (data
not shown). Michaelis-Menten kinetics data indicated that 24 inhibits factor XIa by binding away
from the active site (Figure 44A). To localize the binding site of 24 on factor XIa, we tried
competition with heparin. We expected there to be good competition with heparin due to the fact
that 24 is a derivative of chemoenzymatic lignins, which are known to bind at heparin binding
site of factor XIa, and the fact that it is sulfated. However, to our surprise we found no direct
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competition of 24 with heparin (Figure 44B). To date, no allosteric factor XIa inhibitor was
developed which was incapable of competing with heparin. This fact led us to believe that
compound 24 and its congeners were possibly binding at a novel site, and inducing factor XIa
inhibition by a truly unique mechanism.
Note- The screening, inhibition and allostery was determined with the help of a fellow graduate
student Ms. Malaika D. Argade and have been reported earlier in her master’s thesis. Title:
Discovery and biophysical characterization of allosteric inhibitors of factor XIa (FXIa). (2012).
We therefore pursued the identification of the binding site utilizing molecular modeling.
We confirmed these results by explaining the activities of congeners of 24 and characterizing the
inhibition of 24 with the catalytic domain alone. Lastly, we tested if the binding of 24 to factor
XIa could possibly convert the enzyme back into a zymogen-like conformation.

134

Initial Rate of S-2366
Hydrolysis (mAU/min)

A

80

0nM
300nM
900nM

60
40
20
0
0

0.5

1

[S-2366]
% Residual
Factor XIa Activity

B

150nM
550nM

1.5

(mM)

120
100
0

80

0.42

60

2.4
4

40

16

20

0
-7.5

-6.5

-5.5

Log [24]

-4.5

-3.5

(M)

Figure 44. Compound 24 inhibits factor XIa by allosteric mechanism. (A) Michaelis-Menten
Kinetics of substrate S-2366 hydrolysis in the presence of inhibitor 24 from 0-900 nM. A clear
change in VMAX from 77.4 ± 1.7 to 9.8 ± 0.5 was observed, with relatively no change in K M (0.32
± 0.06 mM), which is characteristic of non-competitive inhibition. (B) Competition of inhibition
of factor XIa by 24 in the presence of varying concentrations of porcine UFH from 0-16 μM. It
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can be seen that there is essentially no change in IC50 even in the presence of 16 μM UFH, which
indicates that 24 inhibits factor XIa allosterically at a site away from the heparin binding site.

5.2 Experimental Procedures
Materials
The recombinant catalytic domain and wild-type full length factor XIa were gifts from Dr.
Alireza Rezaie (Saint Louis University, MO). Dansyl-EGR labeled factor XIa (dEGR-fXIa) was
obtained from Haematologic Technologies (Essex Junction, VT). All other chemicals were
analytical reagent grade from either Sigma Chemicals (St. Louis, MO) or Fisher (Pittsburgh, PA)
and used without further purification.

fXIa Structure Model Generation
Since no crystal structure exists for the activated form of factor XIa, a model for the complete
fXIa was created by replacing the inactive catalytic domain of the zymogen form (PDB id: 2f83)
with the activated catalytic domain crystal structure available (PDB id: 1zom) using Pymol.245
Further, hydrogens were added to the chimera protein and minimized keeping all heavy atoms as
aggregates using Tripos Sybyl-X v.2.1 [www.tripos.com/sybyl].
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Docking of Compound 24
An in silico localization of the possible binding sites for compound 24 was performed using
simple docking protocols. Briefly, the most active compound, 24, was modeled in SybylX 2.1
[www.tripos.com/sybyl] and docked into the structure of the chimera at 8 sites. These sites were
defined as being within 24 Å around residues Lys8, Arg136, Gln153, Lys252, Lys325, Lys357,
Asn566, and Arg584 as shown in Figure 45A. For each site, 1000 genetic algorithm runs were
employed without allowing early termination. Automatic cavity detection was permitted. Docked
poses were scored using GOLDSCORE and only the top two poses were retained. Triplicate
docking runs were employed to ensure the docked poses were reproducible giving us a total of 6
docked poses per site. No constraints were employed because this was an exploratory docking
simulation. Average RMSD across the docked poses was ascertained using in-house code
utilizing the Openeye OEChem toolkit.246

Inhibition of Catalytic Domain of Factor XIa
The inhibition of molecule 24 was tested against the catalytic domain of factor XIa alone using a
microplate assay similar to the one described above. Briefly, in each well 85 µL of buffer (0.05M
Tris, 0.15M NaCl, 0.1% PEG-8000, 0.02% Tween-80 at pH=7.4) was taken, to which was added
5 µL of enzyme fXIa (final concentration of 0.765 nM in each well). Serial dilutions of the
inhibitor stock with decrements of 2/3rd were incubated with the enzyme by addition of 5 μL of
stock inhibitor solutions. The mixture was then incubated for 10 minutes and throughout the
experiment the temperature was maintained at 37°C. After incubation, 5 µL of substrate S-2366
(final concentration of 330 µM) was added to each well and the initial velocities of the reaction
were determined by measuring the absorbance of p-nitroaniline at 405nm released due to
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substrate cleavage by fXIa. The initial rate of substrate hydrolysis was treated using equation 4
and a nonlinear curve fitting was performed to give the IC50 values.

Effect on Protein Anisotropy in Presence of 24 using Perrin Plot
Monitoring protein anisotropy at variable temperatures or viscosities can demonstrate change in
the hydrodynamic radius of the protein. Briefly, in a 96-well microplate, 33 μl of water along
with 5 μl of tris-HCl buffer (to give final concentrations of 50mM tris-HCl and 150mM NaCl
pH=7.4) was added. To this, 20 μl of dansyl-EGR labelled factor XIa (dEGR-fXIa) was added
(final concentration of enzyme was 0.81μM) along with 2 μl of either solvent or 1mM of
compound 24. The wells were read using the FlexStation III, (Molecular Devices, Sunnyvale,
CA) polarization module. The exciation and emission wavelengths were set at 340 nm and 530
nm, respectively. The plate was incubated at various temperatures ranging from 22-40°C for 10
minutes before reading the plate for the parallel (I∥) and perpendicular (I⊥) intensities of
fluorescent light. The average of 13 readings was taken and the anisotropy (r) calculated using
the classical equation.247
∥

(Eq. 10)

∥

The viscosity (η) of the solution at various temperatures (T) was obtained using a calculator
based on previous literature.248,249 A plot of the reciprocal of anisotropy (1/r) versus the T/η
yields a straight line which fits the Perrin equation247:
(Eq. 11)
where, r0 is the fundamental anisotropy of the fluorophore in the absence of diffusion, τ is the
fluorescence lifetime of the fluorophore, R is the gas constant, V is the hydrodynamic volume of
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the protein to which the fluorophore is attached, T is the temperature and η is the viscosity of the
solution. When fit to the equation of a straight line y = mx + c, where y= 1/r, c = 1/r 0 and m =
τRT/Vr0. The ratio of the slopes of the lines corrected for the r0, give the ratio of the
hydrodynamic volumes in the presence and absence of the inhibitor.

5.3 Results
Preparation of a Knowledge-Based Model for Full-Length Factor XIa
Molecular modeling has been used previously to predict binding mode of benzofuran
oligomers to thrombin exosite 2.189 We therefore hypothesized that similar docking studies could
be used to identify the binding site of 24 within factor XIa. However, docking studies require the
existence of a crystal structure of the target protein. To date, there is no complete crystal
structure of full length factor XIa with its four apple domains. The crystal structures of fulllength zymogen form of factor XIa, i.e. factor XI,124 and the catalytic domain of factor XIa250 are
available. This gave us an opportunity to create a model chimera full length factor XIa by simple
replacement of the inactive catalytic domain of the zymogen with the active structure (Figure
45A). Such a model would be physiologically relevant as the protein would be presented in its
zymogen-like inactive state.
Docking Suggests Probable Binding Pose for Benzofuran Trimers
The binding site of benzofuran trimers on fXIa is, as of yet, unknown. We conducted
computational studies to predict the same. Eight areas on the protein surface displayed a
relatively higher positive charge density, and were stochastically nominated as possible binding
sites for 24. The residue approximately at the center of the positively charged patch was
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identified (Figure 45A) and all residues within 24 Å around of it were defined as the binding site.
This covered practically the entire protein surface, ensuring exhaustive exploration during
identification of possible binding sites. The small molecule was then docked into all 8 sites
exhaustively. Any sites where 24 could interact reproducibly would be a plausible binding site.
Five out of 6 docked poses of 24 displayed a very low RMSD (1.6 Å) near Lys252
displayed a very low RMSD (Figure 45B). Moreover, this reproducible pose rationalized the
observed SAR of the benzofuran trimers quite well (Figure 45B, C and D). The lone sulfate of
the trimers present on ring A is required for activity because it forms strong interactions with
Lys255. Note- although the docking center was Lys252, the molecule seemed to localize near
Lys255 near it. When this sulfate is removed in compounds 29, this vital interaction cannot be
formed, resulting in ≈400 fold loss of activity (IC50 = 384 μM). The 6-ethoxy position of the
benzofuran A of the trimer occupies a shallow hydrophobic pocket, where an ethyl group
displayed optimal van der Waal’s interactions. While a methyl group was tolerated here (as in
compound 23 with IC50 = 14.9 μM and 27 with IC50 = 6.4 μM), an isopropyl group displayed
reduced activity because of steric hindrance, as observed in compounds 25 (IC50 = 47μM).
Finally, a negative charge density at the 3-position of the benzofuran C on the trimer, as present
in compounds 29 and 30, was not tolerated because the hydrophobic nature of the binding pocket
and the presence of Glu567 near the trimer.
Interestingly, this binding site is on the A3 domain of fXIa, which is also known to
possess a heparin-binding site (HBS).131,132 Even though compound 24 is sulfated, it binds
adjacent to the HBS, which explains why we did not observe competitive binding with heparin.
While heparin does cause some inhibition of factor XIa activity (~30% with an IC50 ~ 220nM), it
cannot completely inhibit the enzyme compared to 24, indicating that the site of 24 is unique in
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its mechanism and away from the heparin binding site. The strong correlation with
experimentally observed SAR and biophysical studies constitutes conclusive evidence that we
have successfully identified the binding site for these benzofuran trimers on fXIa.

A

C

Arg584

Arg136
Lys357

Lys8

Asn566

Lys252
Gln153
Lys325

B
D
C

B
A

Figure 45. Modeling studies for inhibitor 24. (A)A chimera model was created using the
catalytic domain crystal structure (PDB i.d.: 1zom) and the heavy chain from the zymogen
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crystal structure (PDB i.d.: 2f83). Compound 24 was docked into 8 loci around residues Lys8,
Arg136, Arg184, Lys252, Lys325, Lys357, Asn566, and Arg584,, shown as blue spheres. (B) The
structure docked reproducibly at a site located near residue Lys252, as witnessed by a low
RMSD between the docked poses. (C) Surface features of the site where 24 docked reproducibly,
shows that the sulfate group of 24 interacts well with Lys255. (D) A cartoon representation the
best docked pose of 24 near Lys252 with the interactions highlighted with the binding pocket and
the benzofurans A, B and C. The panels C and D explains the SAR observed. Lys255 interacts
favorably with the sulfate group of 24 – removing the latter eradicates activity. Ethyl groups at
6-ethoxy position of benzofuran A of the benzofuran trimers are ideal for van der Waal’s
contacts with the protein, producing optimum activity. Methyl groups are also tolerated here
because they are smaller, but isopropyl groups reduce activity because the trimers can no longer
fit. Presence of a carboxylate at 3-position of benzofuran C of the trimers is not tolerated due to
the presence of a hydrophobic pocket and two acidic residues (Glu202 and Glu227) which repel
the compounds with acidic functionality here.

Inhibition of Factor XIa by 24 is Apple-Domain Driven
In order to check if the inhibition of factor XIa by 24 is apple domain driven, we tested
24 against the catalytic domain of factor XIa (fXIa-CD) (Figure 46). It was observed that the
IC50 of 24 against fXIa was 1.2 ± 0.2 μM, while that for fXIa-CD was 49 ± 2 μM, indicating that
without the heavy chain of fXIa there is almost a 40-fold reduction in potency.
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Figure 46. Loss in inhibition potency of 24 upon removal of the Apple domains containing the
putative site of binding. Inhibitor 24 shows a 40-fold higher IC50 against the catalytic domain of
factor XIa (, fXIa-CD) in comparion to that against the wild-type fXIa (□).

Inhibition of Factor XIa by 24 Causes a Dramatic Conformational Change in Protein Structure
As the temperature increases, the rotational correlation time (θ) of the protein decreases
due to increased motion. This causes a decrease in anisotropy. The rotational correlation time of
the protein is direct function of the hydrodynamic volume of the protein.247 However, to monitor
such changes, the fluorescence lifetime (τ) of the fluorophore must be comparable to the
rotational correlation time of the protein.251 Hence, we used dansyl labeled factor XIa, as dansyl
has a relatively long fluorescence lifetime.252 We used a Perrin plot (Figure 47) in order to
identify any dramatic changes in the hydrodynamic volume of the protein due to inhibitor
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binding. When fit to the Perrin equation, dEGR-factor XIa gave a best fit line having an
equation:
y = 10.61x10-6x+4.05 (R2 = 0.988),
while in the presence of the inhibitor the equation changed to:
y = 7.50x10-6x + 4.46 (R2 = 0.979).
The reciprocal of the intercept would yield fundamental anisotropy of the fluorophore in
the absence of diffusion (i.e. c=1/r0). This means that in ideal conditions the intercept should
have identical values. However, in practice, fluorophores display segmental motions, which are
independent of overall diffusion when bound to proteins.247 Binding of the inhibitor has been
shown to cause conformational changes within the active site which could affect such segmental
motions and hence there is a small variation between the intercepts of the two plots. When the r0
is corrected for within the slope of the line, the ratio of the slopes would yield the ratio of the
hydrodynamic volumes as all other values are constant under the conditions of the experiment:

(Eq. 12)
The ratio of the corrected slopes (m/c) is 1.55 ± 0.06 suggesting that when 24 binds to
fXIa, it causes a 55 ± 6% increase in the hydrodynamic volume of the protein. Such an increase
would be indicative of a dramatic conformational change within the protein.
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Figure 47. Binding of 24 to factor XIa induces a large conformational change. A Perrin-plot for
dansylated factor XIa (dEGR-fXIa) in the absence (□) and presence (▲) of 24 showing a
significant difference in slope indicating considerably different hydrodynamic volumes of factor
XIa alone and in complex with 24.

5.4 Discussion
Development of inhibitors targeting upstream processes of the coagulation cascade is
gradually gaining speed in order to obtain drugs with fewer side-effects.140 Active site inhibitors
of factor XIa have been synthesized recently (within the last 10 years) but often are either
irreversible by forming a covalent bond with Ser195 or have a strongly basic group to identify
the Asp189 in the S1 pocket of serine proteases.250,253-258 Both these methods of inhibition lead to
lack of selectivity as these features are present on most, if not all, serine proteases.
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Previously synthesized QAOs offered a novel pathway of discovering small-molecule
allosteric inhibition of factor XIa by targeting hydrophobic domains adjacent to heparin-binding
sites.235 They do so by initial coulombic attraction of anionic parts of the ligand (sulfate groups)
to the cationic heparin binding site of fXIa, followed by formation of a tight lock with an
adjacent hydrophobic patch. Although the potency of these molecules was relatively low, with
the lowest IC50 of only 52μM, the study provided impetus to search for a more potent allosteric
inhibitor using similar rationale of coulombic-attraction followed by inhibition using sulfated
small molecule.
Chemo-enzymatically synthesized LMW lignins were found to be potent inhibitors of
factor XIa (Table 1). Yet they suffered from lack of selectivity due to their heterogeneity in their
intermonomeric linkage. Furthermore, SbO4L was found to not have factor XIa inhibitory
potential, suggesting that the lignin factor XIa inhibitory activity possibly arose from other
scaffolds than the β-O4 type lignins.
Our library screen of 65 SSMs took upon the challenge of finding smaller or more potent
analogs, which could possibly inhibit fXIa via allosteric mechanisms. We have successfully
identified at least 8 molecules (Table 10) with an IC50 lower (greater potency) than previously
reported QAOs against fXIa. Furthermore, the predominant class of inhibitors was identified as
the benzofuran dimers and trimers, which are close mimics of the β-5 type linkage found in
lignins.188 The most potent trimer 24 was 50-fold more active than the most active QAO. Trimer
24 was shown to be an allosteric inhibitor of factor XIa, but was surprisingly not competitive
with heparin. We therefore needed to identify the plausible binding site for 24, which might
explain mechanism and help in the development of future inhibitors.
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To explore the possible binding sites for 24 an exhaustive docking search involving 8
sites on a chimera factor XIa model was performed. The search revealed a unique binding site
within the A3 domain of factor XIa which satisfied the SAR observed experimentally.
Additionally it was confirmed that the heavy chain of factor XIa is required for optimal
inhibition by 24, suggesting that a high affinity binding site is located within the apple domains.
The A3 domain has been known to be a key domain for factor XIa activity towards factor
IX activation.137,259 It has also been suggested that Arg184 within the A3 domain sits within a
pocket of the catalytic domain within the zymogen, forming hydrogen bond interactions with
Ser268, Asp488, and Asn566. Upon activation, there is a dramatic change in the catalytic domain
which could release the Arg184 from this cavity and allow it to interact with factor IX. Thus
Arg184 acts as a switch that holds factor XI (zymogen) in an inactive conformation in the
zymogen form. Binding to the proposed binding site of 24 could possibly restrict the movement
of the catalytic domain and force the enzyme into an inactive conformation wherein the “switch”
is in the off-position by restoring Arg184 into the cavity of the catalytic domain, thereby shutting
down the catalytic activity of factor XIa.
We also demonstrated that binding of 24 to factor XIa would cause a dramatic increase in
the hydrodynamic volume of the protein, which is indicative of large conformational changes in
the overall quaternary structure of factor XIa. It is known that the zymogen form of the enzyme
is proportionately larger in size compared to the activated form,128 suggesting that binding of 24
may convert the enzyme back into a conformationally inactive zymogen-like shape.
Our current results highlight the fact that there is a site in the A3 domain of factor XIa
which can be targeted using small aromatic lignin-like molecules with relatively fewer sulfate
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groups to produce potent, allosteric inhibition of factor XIa. Such allosteric inhibition brings
about large conformation change within the protein structure possibly reverting the enzyme into
an inactive zymogen-like conformation. Further structural analysis, mutagenesis studies and
functional bioassays should be performed to confirm the utility of targeting such a site.
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Appendix A. Abbreviations

13C

Carbon

1H

Proton

APTT

Activated partial thromboplastin time

BDMS

bromo dimethyl sulfonium bromide

BSA

Bovine serum albumin

CD

Catalytic domain

dEGR-fXIa

Dansyl-EGR labeled active site factor XIa

DHP

Dehydropolymer

f

Factor

fFPR-Thrombin

Active site fluorescein labeled thrombin

GAG

Glycosaminoglycan

GPIbα

Platelet glycoprotein Ibα

HAS

Hemostasis Analysis System

180

HBS

heparin binding site

HirP

A Tyr63-sulfated hirudin peptide with fluorescein, i.e., [5F]-Hir[5465](SO3-),

HIT

Heparin-induced thrombocytopenia

HLE

Human leukocyte elastase

HMWK

High molecular weight kininogen

LMWH

low molecular weight heparin (enoxaparin)

LRR

Leucine rich repeats

NMR

Nuclear Magnetic Resonance

PAR

Protease activated receptor

PK

Pre-kallikrein

PPE

Porcine pancreatic elastase

PPP

platelet poor plasma

PRP

Platelet rich plasma

PT

Prothrombin time

QAOs

Sulfated quinazolin-4(3H)-ones

RPIP-UPLC-MS

Reversed-phase ion-pairing ultraperformance liquid chromatography
mass spectrometry
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SbO4L

Sulfated β-O4 Lignin

SEC

Size exclusion chromatography

SPGG

Sulfated pentagalloyl glucoside

SPR

Surface plasmon resonance

SSM

Sulfated small molecule

STRAP

Sulfated tyrosine rich anionic peptide

TBDMS

tert-butyl dimethyl silane

TEG

Thromboelastography

TF

Tissue Factor

TH

Thrombin

TM

Thrombomodulin

tPA

Tissue plasminogen activator

TPST

tyrosylprotein sulfotransferase
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